Document:

Exhibit 10.19

 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF
PUBLICLY DISCLOSED.

 

EXCLUSIVE
LICENSE AGREEMENT

 

This
Exclusive License Agreement (this “Agreement”) is entered into
as of January 2, 2022 (the “Effective Date”) by and between Allarity Therapeutics
A/S, a company incorporated under the laws of Denmark, with its principal place of business at Venlighedsvej 1, DK-2970 Hørsholm,
Denmark (“Allarity”), and Oncoheroes Biosciences Inc., a Delaware
corporation, with its principal place of business at 62 Cypress St. #5, Brookline, MA 02445 (“Oncoheroes”). Allarity
and Oncoheroes are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

Whereas,
Oncoheroes is a biopharmaceutical company focused on development of products for pediatric cancers;

 

Whereas,
Allarity is a biopharmaceutical company that possesses certain intellectual property rights related to the pan-targeted kinase inhibitor
Dovitinib pursuant to an Exclusive License Agreement by and between Oncology Venture, ApS (a predecessor of Allarity) and Novartis Pharma
AG dated as of April 6, 2018 (the “Novartis Head License Agreement”); and

 

Whereas,
Allarity desires to grant Oncoheroes an exclusive license under such intellectual property rights, and Oncoheroes desires to obtain a
license under such intellectual property rights, to research, develop and commercialize the Products in the Licensed Field in the Territory
(each capitalized term as defined below), subject to the terms and conditions set forth herein.

 

AGREEMENT

 

Now,
Therefore, in consideration of the foregoing premises
and the mutual promises, covenants and conditions contained in this Agreement, the receipt and sufficiency of which are acknowledged,
the Parties agree as follows:

 

Article
1

Definitions

 

1.1 “Accounting
Standards” means (a) United States generally accepted accounting principles (GAAP) or (b) International Financial
Reporting Standards (IFRS); in each case, as consistently applied throughout the organization of a particular entity and its Affiliates.

 

1.2 “Act”
means, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. §§301 et seq., and all related rules,
regulations and guidelines, as any of the foregoing may be amended from time to time.

 

     

     

    

 

1.3 “Adverse
Event” has the meaning set forth in the Applicable Laws for such term (or comparable adverse safety event term), and will generally
mean any untoward medical occurrence in a patient or human clinical investigation subject administered Product, including occurrences
that do not necessarily have a causal relationship with Product.

 

1.4 “Affiliate”
means, with respect to any Entity (including a Party to this Agreement), any other Entity controlled by, controlling, or under common
control with such Entity. For the purposes of this definition, the term “control” (including, with correlative meanings,
the terms “controlled by” and “under common control with”) means direct or indirect ownership, including ownership
by one or more persons, Entities or trusts with substantially the same beneficial interests, of 50% or more of the outstanding voting
and equity rights of such Entity, or possession of the power to direct the management and policies of such Entity.

 

1.5 “Allarity
Indemnitees” has the meaning set forth in Section 11.1.

 

1.6 “Allarity
Inventions” means any Invention made solely by or on behalf of Allarity, its employees, consultants or contractors, or any
of its Affiliates or licensees (other than Oncoheroes).

 

1.7 “Anti-Corruption
Laws” means the U.S. Foreign Corrupt Practices Act (15 U.S.C. §§78dd-1, et. seq.), as amended, the Organization for
Economic Co-operation and Development (OECD) Convention on combating bribery of foreign public officials in international business transactions,
and any other applicable anti-corruption laws.

 

1.8 “Applicable
Laws” means the applicable provisions of any and all national, supranational, regional, state and local laws, treaties, statutes,
rules, regulations, administrative codes, guidances, ordinances, judgments, decrees, directives, injunctions, orders, permits of or from
any court, arbitrator, Regulatory Authority or governmental agency or authority having jurisdiction over or related to the subject item,
including the Act, and Anti-Corruption Laws.

 

1.9 “Business
Day” means a day other than Saturday, Sunday or a day on which banking institutions in (a) Boston, Massachusetts or (b) Copenhagen,
Denmark are required or permitted to be closed.

 

1.10 “Buy
Back Option” has the meaning set forth in Section 2.2.

 

1.11 “Buy
Back Option Period” means the period commencing upon (a) the earlier to occur of (i) written notice from Allarity to Oncoheroes
that it has received an offer from a pharmaceutical company with at least $250 million of net sales (based upon its most recently-completed
calendar year financial performance) that wishes to acquire global Commercialization rights to the Product in the Licensed Field and
Retained Field; or (ii) completion of the receipt of the first MAA (including an NDA) approval for a Product in any country in the Territory
in the Licensed Field; and (b) ending one hundred-twenty (120) days after the occurrence of the matters set forth in clause (a)(i) and
(a)(ii), as applicable.

 

1.12 “Calendar
Quarter” means the period beginning on the Effective Date and ending on the last day of the Calendar Quarter in which the Effective
Date falls, and thereafter each successive period of three (3) consecutive calendar months ending on the last day of March, June, September,
or December, respectively; provided that the final Calendar Quarter ends on the last day of the Term.

 

    2

     

    

 

1.13 “Calendar
Year” means the period beginning on the Effective Date and ending on December 31 of the Calendar Year in which the Effective
Date falls, and thereafter each successive period of twelve (12) consecutive calendar months beginning on January 1 and ending on December
31; provided that the final Calendar Year ends on the last day of the Term.

 

1.14 “Change
of Control” means with respect to either Party: (a) the acquisition by a Third Party, in one transaction or a series of related
transactions, of direct or indirect beneficial ownership of more than fifty percent (50%) of the then outstanding voting equity securities
or other voting interests of such Party (excluding, for clarity, an acquisition by a Third Party where the stockholders of such acquired
Entity immediately prior to such transaction hold a majority of the voting shares of outstanding capital stock of the surviving entity
immediately following such transaction); (b) any merger, reorganization, consolidation or business combinations involving such Party,
as a result of which a Third Party acquires direct or indirect beneficial ownership of more than fifty percent (50%) of the voting power
of the surviving entity immediately after such merger, reorganization or consolidation; or (c) a sale of all or substantially all of
the assets of such Party in one transaction or a series of related transactions to a Third Party. The acquiring or combining Third Party
in any of (a), (b) or (c), and any of such Third Party’s Affiliates (whether in existence as of or any time following the applicable
transaction, but other than the acquired Party and its Affiliates as in existence prior to the applicable transaction or Affiliates it
controls after the applicable transaction) are referred to collectively herein as the “Acquirer”.

 

1.15 “Clinical
Trial” means any human clinical trial including any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial,
any study incorporating more than one of these phases, or any human clinical trial commenced after Regulatory Approval.

 

1.16 “CMO”
has the meaning set forth in Section 7.1.

 

1.17 “Combination
Product” means a system, package, or combination product or service that involves one or more products or services not Covered
by the Licensed Patents.

 

1.18 “Commercialization”
means any and all activities undertaken before and after obtaining Regulatory Approvals relating specifically to the pre-launch, launch,
promotion, detailing, medical education and medical liaison activities, marketing, pricing, reimbursement, sale, and distribution of
Products, including strategic marketing, sales force detailing, advertising, Product support, all customer support, Product distribution
and invoicing and sales activities; provided, however, “Commercialization” shall exclude any activities relating
to the Manufacture of Product. “Commercialize” and “Commercializing” shall have the correlative
meanings.

 

    3

     

    

 

1.19 “Commercially
Reasonable Efforts” means, with respect to the efforts and resources to be expended, or considerations to be undertaken by
a Party with respect to any objective, activity, or decision to be undertaken hereunder with respect to the Development, Manufacture,
or Commercialization of Product, the reasonable efforts and resources to accomplish such objective, activity or decision that would be
comparable with the efforts and resources normally used by a similarly situated company in the pharmaceutical industry in the exercise
of its reasonable business discretion to accomplish a similar objective, activity or decision for a compound or product owned by it,
or to which it has similar rights, which compound or product is at a similar stage in its development or product life, is in a similar
therapeutic and disease area and is of similar market potential, and in all cases taking into account: (i) the expected and actual competitiveness
of alternative products (including generic or biosimilar products) under development or sold in the marketplace; (ii) the nature and
extent of expected and actual market exclusivity (including patent coverage, regulatory and other exclusivity) of Product; (iii) the
likelihood of Regulatory Approval given the regulatory structure involved, including regulatory or data exclusivity; and (iv) other relevant
factors, including legal, medical, scientific, technical and commercial factors.

 

1.20 “Confidential
Information” of a Party means any and all Information of such Party that is disclosed to the other Party under this Agreement,
whether in oral, written, graphic, or electronic form. In addition, all Information disclosed by Oncoheroes pursuant to the Confidentiality/Non-Disclosure
Agreement between Allarity, and Oncoheroes dated January 12, 2021 (the “Confidentiality Agreement”) is deemed to be
Oncoheroes’ Confidential Information disclosed hereunder, and all Information disclosed by Allarity pursuant to the Confidentiality
Agreement is deemed to be Allarity’s Confidential Information disclosed hereunder; provided that any use or disclosure of any Information
that is authorized under Article 12 shall not be restricted by, or be deemed a violation of, the Confidentiality Agreement.

 

1.21 “Control”
means, with respect to any Product, Know-How, Patents or other intellectual property rights, possession by a Party of the ability (whether
by ownership, license or other right, other than pursuant to a license granted to such Party under this Agreement) to grant access to,
to grant use of, or to grant a license or a sublicense to, such Know-How, Patents or intellectual property rights without violating the
terms of any agreement or other arrangement with any Entity, provided that any Know-How, Patents or intellectual property Controlled
by an Acquirer of a Party shall not be treated as “Controlled” by such Party for purposes of this Agreement, except to the
extent that, and only to the extent that, such Know-How, Patents or intellectual property is actually used by such Acquirer, to Develop,
Manufacture or Commercialize the Product after the Acquirer qualifies as such. Notwithstanding the foregoing, with respect to any intellectual
property acquired after the Effective Date for which a Party will be required to make payments to any Third Party in connection with
the access, licenses and sublicenses granted to the other Party under this Agreement, such Know-How, Patents or intellectual property
shall not be treated as “Controlled” by the licensing Party except to the extent that, and only to the extent that and for
so long as, the other Party agrees and does promptly pay to the licensing Party all such payments arising out of the grant of the license
to the other Party (as mutually agreed between the Parties in good faith).

 

1.22 “Cost
of Goods” means, with respect to Product:

 

(a) in
the case of Product (or any precursuor or intermediate thereof) manufactured by one or more Third Parties, the actual costs of such Manufacturing
invoiced by such Third Party manufacturer to Allarity, including the costs of raw materials, intermediates and components, reference
materials or standards required for release testing, materials necessary to support stability studies (including methods, reference materials
and consumables) drug substance and drug product manufacturing, labeling and packaging, quality assurance and stability testing, characterization
testing, quality control release testing of drug substance and drug product, quality assurance batch record review and release of product,
storage and freight, shipping, tariffs, customs clearance and export fees; and

 

    4

     

    

 

 

(b) in
the case of Product manufactured by a Party or its Affiliate, the (i) actual fully allocated cost of manufacturing such Product, determined
in accordance with Accounting Standards, including the direct and indirect cost of any raw materials, packaging materials and labor utilized
in such manufacturing (including formulation, filling, finishing, quality assurance, quality control, stability testing, release testing,
labeling and packaging, as applicable); and (ii) all other reasonable and customary manufacturing-related costs for such Product, including,
factory, plant or equipment start-up or start-up amortization costs, scale-up expenses, and freight in/out and sales and excise taxes
imposed thereon, customs and duty and charges levied by government authorities, and all costs of packaging, but excluding product inventory
write-offs and failed lots.

 

1.23 “Cover”
means, with respect to a Patent and a Product, that the manufacture, use, offer for sale, sale or import of a Product, absent a license
to such Patent or Product, would infringe a Valid Claim in such Patent; provided, however, that in determining whether a claim
of a pending Patent application would be infringed, it is treated as if issued in the form then currently being prosecuted. “Covered”
and “Covering” have the correlative meanings.

 

1.24 “Development”
means all activities conducted after the Effective Date relating to preclinical and clinical trials, toxicology testing, statistical
analysis, publication and presentation of study results with respect to Products, and the reporting, preparation and submission of regulatory
applications for obtaining, registering and maintaining Regulatory Approval of Products; provided, however, “Development”
shall exclude any activities relating to the Manufacture of Product. “Develop” and “Developing”
shall have the correlative meanings.

 

1.25 “Development
Plan” has the meaning set forth in Section 4.1.

 

1.26 “Dispute”
has the meaning set forth in Section 14.1.

 

1.27 “Distributor”
means a Third Party distributor of Product that: (a) has no royalty or other payment obligations to Oncoheroes or any of its Affiliates
that are calculated based on amounts invoiced or received by such Third Party for sales of Product; or (b)(i) does not take title
to Product, (ii) does not invoice Product sales to Third Party customers, and (iii) is responsible only for inventory management
and distribution with respect to Product on behalf of Oncoheroes or its Affiliate.

 

1.28 “Dollar”
means a U.S. dollar, and “$” shall be interpreted accordingly.

 

1.29 “DRP®
for Dovitinib” means the proprietary, patented DRP® companion diagnostic that Allarity has previously developed and validated
for Dovitinib (in accordance with Allarity’s research which has not received Regulatory Approval), which enables the identification
of likely responders for the drug.

 

    5

     

    

 

1.30 “Drug
Master File” means a drug master file document or right of reference to a drug master file (if the applicable Party does not
have a copy of the underlying drug master file) containing detailed information about the manufacturing of the Product, including information
describing the manufacturing site, the manufacturing facility, the operating procedures, the personnel, the Manufacture, storage and
control of the Product, starting materials and intermediates.

 

1.31 “Drug
Product” means, with respect to any Product, the filled, finished and packaged form of such Product.

 

1.32 “Election
Date” has the meaning set forth in Section 7.3(b).

 

1.33 “EMA”
means the European Medicines Agency or the equivalent Regulatory Authority with competent jurisdiction in the United Kingdom or any successor
entity to either of the foregoing.

 

1.34 “EU”
means the European Union member states as then constituted. As of the Effective Date, the European Union member states are Austria, Belgium,
Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.

 

1.35 “Entity”
means any corporation, general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, company
(including any limited liability company or joint stock company), firm or other enterprise, association, organization or entity.

 

1.36 “Executive
Officer” means, with respect to Allarity, its Chief Executive Officer, and with respect to Oncoheroes, its Chief Executive
Officer, or, in either case, a designee with senior decision-making authority.

 

1.37 “FD&C
Act” means the U.S. Federal Food, Drug and Cosmetic Act, as amended.

 

1.38 “FDA”
means the United States Food and Drug Administration, or any successor agency thereto in the United States

 

1.39 “First
Commercial Sale” means, with respect to a Product in the Licensed Field in the Territory, the first commercial transfer or
disposition for value of such Product by or on behalf of Oncoheroes to a Third Party in the Licensed Field in the Territory after such
Product has received Regulatory Approval (including any pricing approval) in the Licensed Field in the Territory.

 

1.40 “FMV”
has the meaning set forth in Section 2.2.

 

1.41 “GCP”
means current good clinical practices as established by the FDA and as interpreted by relevant ICH guidelines; in each case, as amended
from time to time.

 

1.42 “GLP”
means current good laboratory practices as established by the FDA and as interpreted by relevant ICH guidelines; in each case, as amended
from time to time.

 

    6

     

    

 

1.43 “GMP”
means current good manufacturing practices and standards for the production of drugs and finished pharmaceuticals, as set forth in 21 C.F.R.
Parts 210 and 211, as amended from time to time and as interpreted by relevant ICH guidelines.

 

1.44 “Governmental
Authority” means any multi-national, national, federal, state, local, municipal, provincial or other governmental authority
of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission,
council, court or other tribunal).

 

1.45 “ICH”
means the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.

 

1.46 “IND”
means an investigational new drug application, clinical trial application, clinical trial exemption, or similar application or submission
filed with or submitted to a Regulatory Authority in a jurisdiction that is necessary to commence human clinical trials in such jurisdiction,
including any such application filed with the FDA pursuant to 21 C.F.R. Part 312.

 

1.47 “Indemnified
Party” has the meaning set forth in Section 11.3.

 

1.48 “Indemnifying
Party” has the meaning set forth in Section 11.3.

 

1.49 “Indication”
means a separately defined, well-categorized class of human disease or condition for which a separate MAA (including any extensions or
supplements) is required to be filed with a Regulatory Authority. For clarity, if an MAA is approved for a Product in a particular Indication
and patient population, a label expansion for such Product to include such Indication in a different patient population shall not be
considered a separate Indication.

 

1.50 “Information”
means any data, results, technology, business or financial information or information of any type whatsoever, in any tangible or intangible
form, including know-how, trade secrets, practices, techniques, methods, processes, inventions, developments, specifications, formulations,
formulae, software, algorithms, marketing reports, expertise, technology, test data (including pharmacological, biological and chemical,
biochemical, clinical test data and data resulting from non-clinical studies), CMC information, stability data and other study data and
procedures.

 

1.51 “Infringement”
has the meaning set forth in Section 9.3(a).

 

1.52 “Initiation”
means, with respect to a clinical trial, first dosing of the first subject or patient in such clinical trial.

 

1.53 “Invention”
means any invention or discovery, whether or not patentable, that is made, conceived, generated or reduced to practice, in whole or in
part, in the course and as a result of the conduct of the activities contemplated by this Agreement.

 

1.54 “JDC”
has the meaning set forth in Section 3.1(a).

 

    7

     

    

 

1.55 “Joint
Invention” means any Invention made jointly by (a) on the one hand, one or more employees, consultants or contractors of Oncoheroes
or any of its Affiliates or Sublicensees, and (b) on the other hand, one or more employees, consultants or contractors of Allarity or
any of its Affiliates.

 

1.56 “Joint
Patents” means Patents claiming Joint Inventions.

 

1.57 “Know-How”
means any and all tangible and intangible (a) techniques, technology, practices, trade secrets, inventions (whether patentable or
not), methods, knowledge, know-how, skill, experience, data and results (including pharmacological, toxicological and clinical test data
and results), analytical and quality control data, results or descriptions, software and algorithms, and (b) compositions of matter,
cells, cell lines, assays, animal models and physical, biological or chemical material; that, in each case, are not in the public domain.

 

1.58 “Licensed
Field” means all pediatric oncology Indications, including such pediatric indications as set forth on Exhibit 1.58,
including pediatric osteosarcoma. For the avoidance of doubt, Licensed Field does not include the Retained Field.

 

1.59 “Licensed
Know-How” means all Know-How that (a) is Controlled by Allarity or its Affiliates as of the Effective Date or during the Term,
and (b) is necessary or reasonably useful for the research, Development, Manufacture (provided that such Manufacturing rights shall only
apply when and if a Manufacturing Trigger Event occurs), or Commercialization of Product in the Licensed Field in the Territory.

 

1.60 “Licensed
Patent” means any Patent that (a) is Controlled by Allarity or its Affiliates as of the Effective Date or during the Term,
and (b) Covers (i) a Compound or Product or (ii) the Manufacture of a Compound or Product. A list of Licensed Patents as of the Effective
Date is set forth on Exhibit 1.60.

 

1.61 “Licensed
Technology” means the Licensed Know-How, Licensed Patents, and Licensed Marks. For clarity, Licensed Technology does not include
DRP® for Dovitinib until when and if Allarity does not exercise its Buy Back Option.

 

1.62 “Licensed
Marks” means all Trademarks that (a) are Controlled by Allarity or its Affiliates as of the Effective Date or during the Term
and (b) are used by or on behalf of Allarity as of the Effective Date or during the Term in connection with the Development, Manufacture,
or Commercialization of Product in the Territory. A list of Licensed Marks as of the Effective Date is set forth on Exhibit 1.62.

 

1.63 “MAA”
means an application or submission for approval to market a pharmaceutical product filed with the governing Regulatory Authority.

 

1.64 “Manufacture”
and “Manufacturing” means any activities directed to producing, manufacturing, processing, filling, finishing, packaging,
labeling, quality control, quality assurance testing and release, post-marketing validation testing, inventory control and management,
storing, shipping, and transporting any Product, including oversight and management of vendors therefor. For clarity, manufacturing process
development activities are included within the scope of Manufacturing.

 

1.65 “Manufacturing
Process” has the meaning set forth in Section 7.3(a).

 

    8

     

    

 

1.66 “NDA”
means a New Drug Application (as more fully defined in 21 CFR 314.5, et seq.) filed with the FDA, or any successor application
thereto in the United States.

 

1.67 “Net
Sales” means, on a country-by-country and Product-by-Product basis in the Field in the Territory, with respect to any period
for each country, the gross amounts invoiced by Oncoheroes and its Affiliates (but not Sublicensees) (each, a “Selling Party”),
as applicable, to unrelated Third Parties for sales of a Product in the Field in such country, less the following deductions to the extent
included in the gross invoiced sales price for such Product or otherwise directly paid, incurred, allowed, accrued or specifically allocated
by the Selling Parties with respect to the sale of such Product in such country: (a) discounts, including trade, quantity or cash discounts,
credits, repayments, adjustments or allowances, including those granted on account of price adjustments, billing errors, rejected goods,
damaged goods, recalls or returns, which discounts are applied on a basis consistent with the selling Person’s practices with respect
to the selling Person’s other pharmaceutical products; (b) rebates and chargebacks allowed, given or accrued (including cash, governmental
and managed care rebates, hospital or other buying group chargebacks, cash and non-cash coupons, delayed ship order credits, discounts
related to the impact of price increases between purchase and shipping dates or retroactive price reductions, and governmental taxes
in the nature of a rebate based on usage levels or sales of such Product); (c) any amounts recorded in gross revenue associated with
goods provided to customers for free; (d) freight and insurance charges, customs charges, postage, shipping, handling, REMS compliance
costs and other transportation costs incurred in shipping such Product; (e) fee for service payments to customers for any non-separable
services (including amounts paid or credited to customers for inventory management services); (f) the portion of any management fees
paid during the relevant time period to group purchasing organizations, wholesalers and managed care organizations to the extent determined
by sales or utilization of such Product; and (g) other reductions or specifically identifiable amounts deducted for reasons similar to
these listed above in accordance with Oncoheroes’ Accounting Standards. Net Sales will be determined in accordance with IFRS. Without
limiting the generality of the foregoing, transfers or dispositions of a Product for charitable, promotional (including samples), pre-clinical,
clinical, or regulatory purposes will be excluded from Net Sales, as will sales or transfers of a Product among the Selling Parties.

 

Subject
to the above deductions, Net Sales shall be deemed to occur on, and only on, the first sale by a Selling Party to a non-sublicensee Third
Party. If non-monetary consideration is received by a Selling Party for the Product in the relevant country, Net Sales will be calculated
based on the average price charged for such Product, as applicable, during the preceding period, or in the absence of such sales, the
fair market value of the Product, as applicable, as determined by the Parties in good faith.

 

If
a Product is sold as part of a Combination Product, Net Sales will be the product of (i) Net Sales of the Combination Product calculated
as above (i.e., calculated as for a non-Combination Product) and (ii) the fraction (A/(A+B)), where:

 

“A”
is the gross invoice price in such country of the Product comprising the Compound as the sole therapeutically active ingredient; and

 

“B”
is the gross invoice price in such country of the other therapeutically active ingredients contained in the Combination Product.

 

    9

     

    

 

If
“A” or “B” cannot be determined by reference to non-Combination Product sales as described above, then Net Sales
will be calculated as above, but the gross invoice price in the above equation shall be determined by mutual agreement reached in good
faith by the Parties prior to the end of the accounting period in question based on an equitable method of determining the same that
takes into account, in the applicable country, variation in dosage units and the relative fair market value of each therapeutically active
ingredient in the Combination Product.

 

Notwithstanding
the foregoing, “Net Sales” shall also include any amount received by Oncoheroes or its Affiliates from a Distributor, including
up-front payments, milestone payments, and payments received for or related to the sale or distribution of Products.

 

1.68 “Oncoheroes
Indemnitees” has the meaning set forth in Section 11.2.

 

1.69 “Oncoheroes
Inventions” means any Invention made solely by or on behalf of Oncoheroes, its employees, consultants or contractors, or any
of its Affiliates or Sublicensees.

 

1.70 “Patents”
means (a) all national, regional and international patents and patent applications filed in any country or jurisdiction, including
provisional patent applications, (b) all patent applications filed either from such patents and patent applications or from a patent
application claiming priority from either of these, including any continuation, continuation-in-part, division, provisional, converted
provisional and continued prosecution applications, or any substitute applications, (c) any patent issued with respect to or in
the future issued from any such patent applications including utility models, petty patents and design patents and certificates of invention,
and (d) any and all extensions or restorations by existing or future extension or restoration mechanisms, including revalidations,
reissues, reexaminations and extensions (including any supplementary protection certificates and the like) of the foregoing patents or
patent applications.

 

1.71 “Phase
1 Clinical Trial” means a human clinical trial, that generally provides for the first introduction of a pharmaceutical or biologic
product in humans with a purpose of determining safety, metabolism, and pharmacokinetic properties and clinical pharmacology of such
product, consistent with the requirements of U.S. 21 C.F.R. § 312.21(a) or (for trial conducted outside the United States) its equivalents
in the applicable non-United States jurisdictions.

 

1.72 “Phase
2 Clinical Trial” means a human clinical trial, the principal purpose of which is to explore a variety of doses, dose response,
and duration of effect, and to generate evidence of clinical safety, effectiveness and dose ranging for a particular indication or indications
in a target patient population, consistent with the requirements of U.S. 21 C.F.R. § 312.21(b) or (for trial conducted outside the
United States) its equivalents in the applicable non-United States jurisdictions.

 

1.73 “Phase
3 Clinical Trial” means a human clinical trial, the principal purpose of which is to establish that a product is safe and efficacious
for its indicated use, define contraindications, warnings, precautions and adverse reactions that are associated with the product in
the dosage range to be prescribed, to support the filing of an application for Regulatory Approval for such product, consistent with
the requirements of U.S. 21 C.F.R. §312.21(c) or (for trial conducted outside the United States) its equivalents in the applicable
non-United States jurisdictions.

 

    10

     

    

 

1.74 “Product”
means, Dovitinib (formerly TKI258), which compound (the “Compound”) is a pan-targeted kinase inhibitor, as more specifically
described on Annex I, and including therapeutically-active variants and in the form and formulation existing as of the
Effective Date or any form and formulation such Compound and any salt, ester, hydrate, solvate, prodrug, free acid form, free base form,
crystalline form, co-crystalline form, amorphous form, polymorph, chelate, isomer, enantiomer, racemate, stereoisomer, or tautomer of
any of the foregoing.

 

1.75 “Product
Marks” has the meaning set forth in Section 9.6.

 

1.76 [Intentionally
omitted]

 

1.77 “Regulatory
Approval” means, with respect to a pharmaceutical product in a particular jurisdiction, all approvals or other permissions
from the applicable Regulatory Authority in such jurisdiction necessary to market and sell such product in such jurisdiction, including
pricing and reimbursement approvals if required prior to the first marketing or sale of such product in such jurisdiction.

 

1.78 “Regulatory
Authority” means any applicable Governmental Authority having the administrative authority to regulate the manufacturing, development,
commercialization, reimbursement or pricing, as applicable, for the Product, including Regulatory Approvals, including the FDA and the
EMA.

 

1.79 “Regulatory
Exclusivity” means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect
to a pharmaceutical product other than a Patent, including orphan drug exclusivity, new chemical entity exclusivity, data exclusivity,
or pediatric exclusivity.

 

1.80 “Regulatory
Filings” means all INDs, NDAs, MAAs, Regulatory Approvals, and other filings (including any Drug Master File (if any)) with,
and formal submissions to, Regulatory Authorities, in each case, with respect to Product in any country or other jurisdiction.

 

1.81 “Retained
Field” means all uses other than the Licensed Field.

 

1.82 “Right
of Reference” means: (a) in the United States, a “right of reference or use,” as such term is defined in 21 C.F.R. 314.3(b);
or (b) in any other country or jurisdiction, the equivalent authority to rely upon, and otherwise use, an investigation for the
purpose of filing, and conducting a clinical trial under, an IND, or obtaining approval of an NDA, MAA or other Regulatory Approval,
including the ability to make available the underlying raw data from the investigation for audit by the applicable Regulatory Authority
in such country or other jurisdiction, if necessary.

 

    11

     

    

 

1.83 “Royalty
Term” means, on a Product-by-Product and country-by-country basis, the period of time commencing on the First Commercial Sale
of any Product in such country and expiring on the later of (a) expiration of the last Valid Claim of any and all Licensed Patents (as
defined in the Novartis Head License Agreement) Covering such Product in such country; (b) the expiration of Regulatory Exclusivity for
such Product in such country; and the tenth (10th) anniversary of the date of First Commercial Sale of such Product in such
country; provided that, with respect to a Product being Commercialized in the US and the Major Countries, the Royalty Term shall continue
in both the US and the Major Countries until expiration of the last Valid Claim of any and all Licensed Patents Covering such Product
in the US and each of the countries in the Major Countries; it being understood and agreed that all of the terms which are capitalized
and not defined in this definition of “Royalty Term” shall have the meanings ascribed to such terms in the Novartis Head
License Agreement.

 

1.84 “Sublicensee”
means any Third Party that has received a sublicense of the rights granted to Oncoheroes under Section 2.1(a), directly or indirectly
through one or more tiers, from Oncoheroes or its Affiliate. As used in this Agreement, “Sublicensee” excludes a Distributor.

 

1.85 “Supply
Agreement” has the meaning set forth in Section 7.1.

 

1.86 “Technology
Transfer” has the meaning set forth in Section 7.3(b).

 

1.87 “Term”
has the meaning set forth in Section 13.1.

 

1.88 “Territory”
means all countries of the world.

 

1.89 “Third
Party” means any Entity other than Oncoheroes or Allarity or an Affiliate of Oncoheroes or Allarity.

 

1.90 “Trademark”
means any word, name, symbol, color, shape, designation or device or any combination thereof, including any trademark, service mark,
trade name, trade dress, brand name, product configuration, domain name, logo, design or business symbol, that functions as an identifier
of source, origin or membership, whether or not registered, and all statutory and common law rights therein, and all registrations and
applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing.

 

1.91 “Upstream
License” means any agreement between Allarity (or any of its Affiliates) and any Third Party (such Third Party, an “Upstream
Licensor”) pursuant to which Allarity Controls any Know-How or Patents that are included in the Licensed Technology. The Upstream
Licenses existing as of the Effective Date are set forth in Exhibit 1.91.

 

1.92 “U.S.”
means the United States of America, including all possessions and territories thereof.

 

1.93 “Valid
Claim” means (a) a claim of an issued, unexpired patent within the Licensed Patents that has not been revoked, disclaimed,
abandoned or held invalid or unenforceable by a court or other body of competent jurisdiction in an unappealed or unappealable decision
and (b) a claim of any patent application within a Licensed Patent which has not been abandoned or finally disallowed without the possibility
of appeal or re-filing of the application and has not been pending for a period of more than seven (7) years.

 

    12

     

    

 

Article
2

LICENSES AND EXCLUSIVITY

 

2.1 License
to Oncoheroes.

 

(a) License
to Oncoheroes. Subject to the terms and conditions of this Agreement, Allarity hereby grants Oncoheroes an exclusive (even as to
Allarity and its Affiliates), royalty-bearing license, with the right to sublicense through multiple tiers in accordance with Section
2.1(b), under the Licensed Technology to research, Develop, Manufacture (provided that such Manufacturing rights shall only apply when
and if a Manufacturing Trigger Event (defined below) occurs), have Manufactured, use, sell, have sold, offer for sale, import, export
and otherwise Commercialize Products in the Licensed Field in the Territory; it being understood and agreed that only with respect to
the licensed Platform Patents set forth in Exhibit 1.60 (and as defined in the Novartis Head License Agreement) and Manufacturing Technology
(as defined in the Novartis Head License Agreement), such license shall be non-exclusive; it being further understood and agreed that
Licensed Technology does not include DRP® for Dovitinib until, when and if Allarity does not exercise its Buy Back Option, in which
event the license granted to Oncoheroes shall be amended to include such license for the DRP® for Dovitinib in the Licensed Field.
“Manufacturing Trigger Event” means the earlier to occur of (a) Allarity does not exercise its Buy Back Option pursuant
to Section 2.2; (b) the Parties (or Oncoheroes and Allarity’s CMO) despite good faith negotiations fail to enter into a Supply
Agreement pursuant to Section 7.1 within sixty (60) days after Oncoheroes’ request to obtain supply of Product from Allarity or
Allarity’s CMO; and (c) in the event that Allarity (rather than Allarity’s CMO) enters into a Supply Agreement, the failure
of Allarity to supply at least fifty percent (50%) of Oncoheroes forecasted demand of Product pursuant to the Supply Agreement for two
(2) consecutive Calendar Quarters.

 

(b) Sublicenses.

 

(i) Oncoheroes
shall have a right to grant sublicenses under the Licensed Technology to its Affiliates (but only for so long as Affiliate remains an
Affiliate of Oncoheroes). Additionally, Oncoheroes shall have a right to grant sublicenses under the Licensed Technology to Third Parties
upon completion of the first Phase 2 Clinical Trial of a Product, provided that, the right to grant sublicenses to Third Parties shall
only apply when and if Allarity does not exercise its Buy Back Option pursuant to Section 2.2.

 

(ii) Each
agreement in which Oncoheroes grants a sublicense under the Licensed Technology shall be consistent with the terms and conditions of
this Agreement applicable to the scope of the sublicense granted to a Sublicensee and Oncoheroes shall ensure that its Sublicensees comply
with the applicable terms and conditions of this Agreement.

 

(iii) Notwithstanding
any such sublicense, Oncoheroes shall remain solely liable for the performance of its obligations hereunder, regardless of whether such
obligation is delegated, subcontracted, or sublicensed to any of its Affiliates, Subcontractors or Sublicensees.

 

    13

     

    

 

(iv) Oncoheroes
shall provide Allarity with (w) a then-current copy of the proposed term sheet with a Sublicensee at least ten (10) Business Days prior
to the expected execution or finalization of such term sheet, (x) a then-current copy of each proposed sublicense agreement with a Sublicensee
at least ten (10) Business Days prior to the expected execution of such sublicense agreement and (y) a true and complete copy of each
sublicense agreement with a Sublicensee within thirty (30) days after the execution of such sublicense agreement; provided, that,
in each case of a Sublicense to a Third Party, Oncoheroes may redact certain terms of any such sublicense agreement if such terms are
not (i) related to either Party’s rights or obligations under this Agreement, or (ii) necessary for Allarity to verify Oncoheroes’
compliance with this Agreement.

 

(c) Subcontractors.
Oncoheroes may appoint Distributors and engage subcontractors (including contract research organizations) who confirm and agree in writing
to be bound by the terms and conditions of this Agreement (“Subcontractors”) for the purpose of performing Oncoheroes’
obligations, subject to Section 2.1(b)(iii), with respect to the Development, Manufacture, and Commercialization of Product in the Licensed
Field in the Territory.

 

(d) Non-Compete.
Except pursuant to this Agreement:

 

(i) Neither
Party nor its Affiliates shall, at any time during the Term, either on its own behalf or through any Affiliate or Third Party, directly
or indirectly make, market, promote, sell, offer for sale, import, export or otherwise Commercialize any (a) Competitive Product in the
Licensed Field, or (b) any other formulations of the Compound, or in-license or otherwise acquire any product that is a Competitive Product
or other formulation of the Compound, in the Licensed Field anywhere in the Territory.

 

(ii) As
used in this Agreement, “Competitive Product” means, other than the Product, any pharmaceutical product having a primary
mechanism of action (or in the case of a combination product, any component of such combination product having as its primary mechanism
of action) through the inhibition of multiple receptor tyrosine kinases, whether currently marketed or in development, that is labeled,
advertised, marketed, promoted or intended for use in the Licensed Field.

 

(iii) Notwithstanding
Section 2.1(d) above, if a Change of Control occurs with respect to a Party and, in each case, the Acquiror (or any of such Acquiror’s
then-existing Affiliates) already has, or the acquired assets contain, as applicable, a program that existed prior to the Change of Control
that would otherwise violate Section 2.1(d) above at the time of such Change of Control (a “Business Program”), then
such Acquiror (or such Acquiror’s Affiliate) or such Party, as applicable, shall be permitted to continue such Business Program
after the closing of such Change of Control and such continuation shall not constitute a violation of 2.1(d) above provided that (i)
none of the Licensed Technology licensed under this Agreement shall be used in the Business Program, and (ii) the research or development
activities required under this Agreement shall be segregated from any research or development activities directed to such Business Program,
including the maintenance of separate lab notebooks and records (password-protected to the extent kept on a computer network) and the
use of separate personnel to perform the activities under this Agreement and the activities covered under such Business Program. The
Party undergoing the Change of Control shall adopt reasonable procedures to limit the dissemination of the other Party’s Confidential
Information to only those personnel having a need to know such Confidential Information in order for such Party or the Acquiror, as applicable,
to perform its obligations or to exercise its rights under this Agreement, including adopting reasonable procedures and policies that
prohibit and limit the use and disclosure of such Confidential Information in a competitive manner against the other Party and its Affiliates,
and adopting reasonable procedures and policies that prohibit or limit such Confidential Information from being disclosed to or used
by any Person who is also working on or making scientific, intellectual property or commercial decisions regarding the Competitive Product
at the time of receipt or use of any such Confidential Information, or within three (3) years following receipt or use of any such Confidential
Information.

 

    14

     

    

 

2.2 Buy
Back Option. Oncoheroes hereby grants to Allarity an exclusive option, during the Buy Back Option Period, to reacquire the rights
granted to Oncoheroes under this Agreement to the Product in the Licensed Field (the “Buy Back Option”). Allarity
may exercise the Buy Back Option by submitting a written offer prior to the expiration of the Buy Back Option Period. Upon the timely
exercise of the Buy Back Option, (i) any Development Milestone payments due from Oncoheroes to Allarity shall be cancelled, and (ii)
the Parties shall enter into exclusive good faith negotiations regarding a fair market value (“FMV”) payment to Oncoheroes
which will take into account the value generated by Oncoheroes to the Product, and may include a one-off payment to Oncoheroes and royalties
on future Net Sales for the Product, or a one-time upfront payment, or such other FMV as the Parties shall negotiate in good faith. In
the event that the Parties are unable to agree upon the FMV payments within sixty (60) days, then either Party may elect to have a mutually
agreed upon evaluation expert determine the FMV as follows: (a) each Party will submit its proposed FMV proposal to such expert within
ten (10) days following such expert retention; and (b) within thirty (30) days of such expert retention, such expert shall be authorized
and directed to only select the FMV proposal of either Party which such Expert believes most closely reflects the FMV payment contemplated
above, all in accordance with Section 14.4. Such expert determination will be final and binding on both Parties, and the cost of such
expert shall be borne by the Party requesting such expert determination.

 

2.3 No
Implied Licenses. Except as explicitly set forth in this Agreement, neither Party shall be deemed by estoppel or implication to have
granted the other Party any license or other right to any intellectual property of such Party.

 

2.4 Transfer
of Licensed Know-How. Promptly after the Effective Date, pursuant to a transfer plan agreed to by the Parties through the JDC, Allarity
shall provide Oncoheroes with complete and accurate copies of all Licensed Know-How in writing and existence as of the Effective Date
reasonably necessary to Develop, Manufacture, or Commercialize the Products in the Licensed Field in the Territory. For a period of up
to one (1) year after the Effective Date, Allarity shall (i) provide Oncoheroes with complete and accurate copies in writing of all Licensed
Know-How generated since the last such transfer under this Section 2.4, copies of which shall be provided in writing; and (ii) use commercially
reasonable efforts to provide reasonable consultation, and assistance for the purpose of transferring to Oncoheroes all such Licensed
Know-How to the extent reasonably necessary or reasonably useful for Oncoheroes to Develop, Manufacture, or Commercialize Product in
the Licensed Field in the Territory, and Oncoheroes shall be responsible for any and all Third Party costs or costs incurred by Allarity
related to such consultation and assistance.

 

    15

     

    

 

Article
3

GOVERNANCE

 

3.1 Joint
Development Committee.

 

(a) Formation
and Role. Promptly, and in any event within thirty (30) days after the Effective Date, the Parties shall establish a joint development
committee (the “JDC”) to coordinate, oversee, review and discuss the Parties’ activities with respect to the
research and Development, of Products. For that purpose and to the extent reasonably necessary, the JDC will:

 

(i) discuss
the status, progress and results of all Development activities conducted by or on behalf of either Party with respect to Product, both
in and outside the Licensed Field, in the Territory;

 

(ii) facilitate
communications and discussions between the Parties with respect to the Development Plan;

 

(iii) review,
discuss, and approve any proposed amendments or revisions to the Development Plan;

 

(iv) oversee,
coordinate, and discuss the status, progress and results of all Manufacturing activities (including process development) conducted by
or on behalf of either Party with respect to Product;

 

(v) oversee
technology transfer from Allarity to Oncoheroes;

 

(vi) review
and discuss significant correspondence to or from a Regulatory Authority (including submissions of Regulatory Filings) that are relevant
to Product in both the Licensed Field and the Retained Field; and

 

(vii) perform
such other functions as appropriate to further the purposes of this Agreement, as expressly set forth in this Agreement or as determined
by the Parties in writing.

 

The
JDC shall have only the powers expressly assigned to it in this Section 3.1 and elsewhere in this Agreement, and shall have no power
to amend, modify, or waive compliance with this Agreement.

 

(b) Members.
The JDC shall consist of five (5) members. Oncoheroes shall appoint three (3) representatives to the JDC, and Allarity shall appoint
two (2) representatives to the JDC. Each JDC representative may be an officer, employee, or representative of the applicable Party having
sufficient experience and knowledge of matters arising within the scope of the JDC’s responsibilities to make decisions with respect
thereto. Each Party may replace its representatives at any time upon written notice to the other Party. The JDC shall have an alternating
chairperson selected by the Parties on an annual basis, with the first chairperson convening the initial meeting selected by Allarity.
The role of the chairperson shall be to convene and preside at the meetings of the JDC and to ensure the preparation of meeting minutes,
but, except as set forth in Section 3.1(c), the chairperson shall have no additional powers or rights beyond those held by other JDC
representatives.

 

    16

     

    

 

(c) Meetings.
The JDC shall meet at least one (1) time per Calendar Quarter, unless the Parties mutually agree in writing to a different frequency
for such meetings or no further development is contemplated. Either Party may also call a special meeting of the JDC (by videoconference
or teleconference) by at least ten (10) Business Days’ (or fewer, if the Parties agree) prior written notice to the other Party
in the event such Party reasonably believes that a significant matter must be addressed prior to the next regularly scheduled meeting,
and such Party shall provide the JDC, no later than ten (10) Business Days prior to the special meeting, with materials reasonably adequate
to enable an informed decision. No later than ten (10) Business Days prior to any meeting of the JDC, the chairperson of the JDC shall
prepare and circulate an agenda for such meeting; provided, however, that either Party may propose additional topics to be included
on such agenda, either prior to or in the course of such meeting. The JDC may meet in person, by videoconference or by teleconference,
as the Parties agree. Each Party shall bear the expense of its respective JDC members’ participation in JDC meetings. A reasonable
number of additional representatives of a Party may attend meetings of the JDC in a non-voting capacity, provided that such additional
members are bound in writing by obligations of confidentiality at least as restrictive as those contained in this Agreement. Meetings
of the JDC are effective only if at least one (1) representative of each Party is present or participating in such meeting. The chairperson
of the JDC is responsible for preparing reasonably detailed written minutes of all JDC meetings that reflect, without limitation, all
material decisions made at such meetings. The JDC chairperson shall send draft meeting minutes to each member of the JDC for review and
approval within ten (10) Business Days after each JDC meeting. Such minutes will be deemed approved unless one or more members of the
JDC object to the accuracy of such minutes within ten (10) Business Days of receipt.

 

(d) Decision-Making.
The JDC shall act by simple majority vote of the Parties’ representatives. The representatives from each Party will each have one
(1) vote. If after reasonable discussion and good faith consideration of each Party’s view on a particular matter before the JDC,
the JDC cannot reach a simple majority vote as to such matter within twenty (20) days after such matter was brought to the JDC for resolution,
then such matter shall be referred to Executive Officers for resolution. If the issue is not resolved within twenty (20) days following
the referral of such issue to the Executive Officers, then Oncoheroes shall have final decision-making authority with respect to any
matters relating solely to, or that solely impact, the Development and Manufacturing, of the Product in the Licensed Field (provided
that, Oncoheroes may not make any decision or take any action that (I) could reasonably be expected to materially, adversely impact
the Product outside the Licensed Field or breach the terms and conditions of the Novartis Head License Agreement, (II) requires Allarity
to provide any resources or bear any costs except as expressly required under this Agreement, or (III) involves any dispute regarding
obligations or rights under this Agreement or would reasonably be expected to violate Oncoheroes’ obligations under this Agreement,
in each case (of subclauses (I)-(III)) without first obtaining Allarity’s prior written consent, which consent may be withheld
in Allarity’s sole discretion). For clarity, the Parties shall continue to perform all obligations of this Agreement during the
foregoing decision-making process.

 

    17

     

    

 

3.2 Scope
of Authority. Notwithstanding the establishment and existence of the JDC or any subcommittee, each Party shall retain the rights,
powers and discretion granted to it hereunder, and neither the JDC nor any subcommittee is delegated or vested with rights, powers or
discretion unless such delegation or vesting is expressly provided herein. The JDC has no decision-making authority with regard to any
expansion of the Development activities under this Agreement.

 

3.3 Subcommittees.
From time to time, the JDC may establish additional subcommittees to oversee particular projects or activities within the scope of authority
of the JDC, as it deems necessary or advisable. Each subcommittee will be composed of an equal number of representatives of each Party,
as the JDC determines is appropriate from time to time, and will meet with such frequency as the JDC determines. If, with respect to
a matter that is subject to a subcommittee’s decision-making authority, the subcommittee cannot reach unanimity, the subcommittee
will refer the matter to the JDC for resolution.

 

Article
4

DEVELOPMENT

 

4.1 Development.

 

(a) In
the Licensed Field. Oncoheroes has the exclusive right to conduct, and is solely responsible for all aspects of, the Development
of Product, including conducting Clinical Trials for Product, in the Licensed Field, it being understood and agreed that the initial
Clinical Trial for Product shall be for the treatment for pediatric osteosarcoma or such other pediatric oncology Indication as may be
mutually agreed upon by the Parties based upon feedback from the applicable Regulatory Authority. As between the Parties, Oncoheroes
shall bear all of its costs and expenses incurred in connection with such Development activities.

 

(b) Development
Plan. Oncoheroes shall Develop Product in the Licensed Field in the Territory pursuant to the Development Plan. Oncoheroes shall
provide Allarity with an initial, high level development plan (the “Initial Development Plan”) within thirty (30)
days after the Effective Date. Within sixty (60) days after the Effective Date, Oncoheroes will prepare and submit to the JDC a detailed
plan containing the strategy, activities, study designs, timeline and budget for clinical research and Development of the Product in
the Licensed Field (the “First Supplemental Development Plan,” and together with the Initial Development Plan and
any subsequent updates pursuant to this Section 4.1, the “Development Plan”). The First Supplemental Development
Plan shall include among other things, all clinical studies, and regulatory activities with respect to the Product to be conducted by
or on behalf of Oncoheroes or its Affiliates or their respective Sublicensees in the Licensed Field.

 

(c) Amendments
to the Development Plan. From time to time during the Term, but at least every six (6) months, Oncoheroes shall propose amendments
to the Development Plan and submit such proposed amended Development Plan to the JDC for review, discussion, and approval in accordance
with Section 3.1(a)(iii). Each amended Development Plan becomes effective on the date of approval by the JDC. References to the
“Development Plan” in this Agreement refer to the Development Plan as then in effect (including all amendments thereto).

 

    18

     

    

 

(d) In
the Retained Field. Allarity has the exclusive right to conduct, and is solely responsible for all aspects of, the Development of
Product, including conducting Clinical Trials for Product, in the Retained Field. As between the Parties, Allarity shall bear all of
its costs and expenses incurred in connection with such Development activities.

 

(e) Companion
Diagnostic. Oncoheroes shall develop the Products together with the DRP® for Dovitinib as a companion diagnostic. For European
Clinical Trials, Allarity shall support such clinical development by running the DRP® for Dovitinib on clinical biopsy materials
provided by Oncoheroes to identify likely responder patients. Allarity shall provide such support at its own cost. For U.S. Clinical
Trials, Allarity shall facilitate DRP® testing support at the expense of Oncoheroes.

 

(f) CMC
Support. Upon the request of the other Party, each Party sill provide reasonable assistance with respect to chemistry, manufacturing
and controls (“CMC”) support in relation to the Development activities for the Product in the Licensed Field.

 

4.2 Development
Diligence. Oncoheroes, itself or through its Affiliates, Sublicensees, or Subcontractors, shall use Commercially Reasonable Efforts,
at its sole cost and expense, to Develop the Product in the Licensed Field in the Territory, including to achieve the development milestone
events by certain target dates contained in the Development Plan. Oncoheroes shall, and Oncoheroes shall cause its Affiliates, Sublicensees
and its Subcontractors to, conduct all Development under this Agreement in a professional manner and in compliance with all Applicable
Laws, including applicable GLP, cGMP and GCP and, as between the Parties, Oncoheroes shall be responsible for the performance of each
such person.

 

4.3 Development
Updates. Each Party shall keep the other Party reasonably informed, through the JDC, of the status, progress, and results of all
Development activities for Product, both in and outside the Licensed Field, in the Territory. Each Party shall promptly respond to reasonable
requests of the other Party for additional Information with respect to such other Party’s Development activities for Product, both
in and outside the Licensed Field, in the Territory.

 

4.4 Records
and Reports. Each Party shall prepare and maintain, or shall cause to be prepared and maintained, in conformity with standard pharmaceutical
and biotechnology industry practices and the terms and conditions of this Agreement, complete and accurate written records, accounts,
notes, reports and data with respect to all Development activities with respect to Product. Such records shall fully and properly reflect,
in good scientific manner appropriate for regulatory and patent purposes, all work done and results achieved in the performance of all
Development activities for Product, both in and outside the Licensed Field, in the Territory. Each Party shall document all non-clinical
studies and clinical trials in formal written study records, and shall document all manufacturing activities for Products, in each case
in accordance with Applicable Laws, including applicable national and international guidelines such as ICH, GCP, GLP and GMP. The Parties
shall discuss the status, progress and results of all Development activities with respect to Product, both in and outside the Licensed
Field, in the Territory at such JDC meetings.

 

    19

     

    

 

4.5 Development
Data.

 

(a) Each
Party shall solely own all data, records and reports generated by or on behalf of such Party, its Affiliates or Sublicensees (with respect
to Oncoheroes), in the non-clinical and clinical Development of the Product (the “Product Data”); provided,
that neither Party is deemed to conduct Development of the Product on behalf of the other Party. Notwithstanding any provision of this
Agreement to the contrary, Product Data that a Party is required to deliver to the other Party under this Agreement shall be limited
to Product Data that is (a) Controlled by such Party and (b) that is necessary or reasonably useful to support the Development, Regulatory
Approval or Commercialization of the Products.

 

(b) Each
Party, shall, on a Calendar Quarterly basis and at no charge to the other Party, as permitted under Applicable Law (including GCP), provide
the other Party with a summary of all Product Data not previously transferred under this Section 4.5. Allarity may disclose and
provide copies of such Product Data Controlled by Oncoheroes to Allarity’s Affiliates and Third Party licensees that have agreed
in writing to share development data with Allarity and Oncoheroes on terms substantially similar to the terms of this Section 4.5. Oncoheroes
may disclose and provide copies of such Product Data Controlled by Allarity to Oncoheroes’ Affiliates and Sublicensees that have
agreed in writing to share development data with Allarity and Oncoheroes on terms substantially similar to the terms of this Section
4.5.

 

4.6 Standards
of Conduct. Each Party shall perform, and shall ensure that its Affiliates, Sublicensees and Third-Party contractors perform, the
Development activities with respect to Product in good scientific manner, and in compliance in all material respects with the requirements
of Applicable Law and the Novartis Head License Agreement.

 

Article
5

REGULATORY

 

5.1 Overview.

 

(a) In
the Licensed Field. Oncoheroes has the exclusive right to conduct, and subject to the remainder of this Article 5, is solely responsible
for all aspects of, activities related to (a) setting the regulatory strategy for seeking Regulatory Approvals (including any pricing
approvals) for Products in the Licensed Field in the Territory, and (b) seeking and obtaining Regulatory Approvals in the Licensed Field
in the Territory. As between the Parties, Oncoheroes shall bear all of its costs and expenses incurred in connection with such regulatory
activities.

 

(b) In
the Retained Field. Allarity has the exclusive right to conduct, and subject to the remainder of this Article 5, is solely responsible
for all aspects of, activities related to (a) setting the regulatory strategy for seeking Regulatory Approvals (including any pricing
approvals) for Products in the Retained Field in the Territory, and (b) seeking and obtaining Regulatory Approvals in the Retained Field
in the Territory. As between the Parties, Allarity shall bear all of its costs and expenses incurred in connection with such regulatory
activities.

 

    20

     

    

 

5.2 Regulatory
Responsibilities and Rights of Reference.

 

(a) In
the Licensed Field. Oncoheroes shall prepare, submit, and own all Regulatory Filings for Product in the Licensed Field in the Territory,
at Oncoheroes’ sole cost and expense. Allarity hereby grants to Oncoheroes a Right of Reference to all Regulatory Filings pertaining
to Product submitted by or on behalf of Allarity, including any such Regulatory Filings that are in the possession of any Third Party,
subject to the prior written consent of such Third Party. Oncoheroes may use such Right of Reference to Allarity’s Regulatory Filings
solely for the purpose of seeking, obtaining, and maintaining Regulatory Approval of Product in Licensed Field in the Territory, including
in interactions with any Regulatory Authority in connection with Development or Regulatory Approval of Product in the Licensed Field
in the Territory. Allarity shall support Oncoheroes, as reasonably requested by Oncoheroes and at Oncoheroes’ expense, in seeking,
obtaining, and maintaining Regulatory Approvals in the Licensed Field in the Territory, including providing necessary documents or other
materials required by Applicable Law to seek, obtain, or maintain Regulatory Approval in the Licensed Field, all in accordance with the
terms and conditions of this Agreement. Oncoheroes shall lead all interactions with Regulatory Authorities with respect to Products in
the Licensed Field in the Territory. Oncoheroes shall keep Allarity reasonably informed of any material regulatory developments related
to Products in the Licensed Field in the Territory. At each regularly scheduled JDC meeting, Oncoheroes shall provide Allarity with a
list and schedule of any in-person meeting or teleconference with the applicable Regulatory Authorities (or related advisory committees)
in the Territory planned for the next Calendar Quarter that relates to any Product in the Licensed Field. In addition, Oncoheroes shall
notify Allarity as soon as reasonably possible (but in no event later than three (3) Business Days if possible) after Oncoheroes becomes
aware of any additional such meetings or teleconferences that become scheduled for such Calendar Quarter. Allarity shall provide all
assistance and documentation reasonably requested by Oncoheroes to prepare for any such meeting or teleconference, including making available
competent personnel to attend any such meeting or teleconference, at Oncoheroes’ reasonable request. To the extent permitted by
Applicable Laws and by the Regulatory Authorities (as reasonably determined by Oncoheroes), Allarity shall have the right to attend and
observe such meetings and teleconferences, and, upon the mutual agreement of the Parties, participate in such meetings and teleconferences,
in each case at Allarity’s cost (unless such attendance and participation was requested by Oncoheroes).

 

(b) In
the Retained Field. As between the Parties, Allarity shall prepare, submit, and own all Regulatory Filings for Product in the Retained
Field in the Territory, at Allarity’s sole cost and expense. Oncoheroes hereby grants to Allarity a Right of Reference to all Regulatory
Filings pertaining to Product submitted by or on behalf of Oncoheroes. Allarity may use such Right of Reference to Oncoheroes’
Regulatory Filings solely for the purpose of seeking, obtaining, and maintaining Regulatory Approval of Product in the Retained Field
in the Territory, including in interactions with any Regulatory Authority in connection with Development or Regulatory Approval of Product
in the Retained Field in the Territory. Oncoheroes shall support Allarity, as reasonably requested by Allarity and at Allarity’s
expense, in seeking, obtaining, and maintaining Regulatory Approvals in the Retained Field in the Territory, including providing necessary
documents or other materials required by Applicable Law to seek, obtain, or maintain Regulatory Approval in the Retained Field, all in
accordance with the terms and conditions of this Agreement. Allarity shall lead all interactions with Regulatory Authorities with respect
to Products in the Retained Field in the Territory. Allarity shall keep Oncoheroes reasonably informed of any material regulatory developments
related to Products in the Retained Field in the Territory. At each regularly scheduled JDC meeting, Allarity shall provide Oncoheroes
with a list and schedule of any in-person meeting or teleconference with the applicable Regulatory Authorities (or related advisory committees)
in the Territory planned for the next Calendar Quarter that relates to any Product in the Retained Field. In addition, Allarity shall
notify Oncoheroes as soon as reasonably possible (but in no event later than three (3) Business Days if possible) after Allarity becomes
aware of any additional such meetings or teleconferences that become scheduled for such Calendar Quarter. Oncoheroes shall provide all
assistance and documentation reasonably requested by Allarity to prepare for any such meeting or teleconference, including making available
competent personnel to attend any such meeting or teleconference, at Allarity’s reasonable request.

 

    21

     

    

 

5.3 Regulatory
Authority Inspection.

 

(a) Inspections
of Oncoheroes. Oncoheroes shall immediately notify Allarity as soon as Oncoheroes becomes aware of any Regulatory Authority inspections
relating to any Product in the Licensed Field in the Territory. Allarity may be present at any such inspections and Oncoheroes shall
provide Allarity the opportunity to review and comment on any responses that may be required. If Oncoheroes does not receive prior notice
of any such inspection, Oncoheroes shall notify Allarity as soon as practicable after such inspection and shall provide Allarity with
copies of all materials, correspondence, statements, forms and records received or generated pursuant to any such inspection.

 

(b) Inspections
of Allarity. Allarity shall immediately notify Oncoheroes as soon as Allarity becomes aware of any Regulatory Authority inspections
relating to any Product in the Retained Field in the Territory. If Allarity does not receive prior notice of any such inspection, Allarity
shall notify Oncoheroes as soon as practicable after such inspection and shall provide Oncoheroes with copies of all materials, correspondence,
statements, forms and records received or generated pursuant to any such inspection.

 

5.4 Regulatory
Cooperation.

 

(a) Each
Party shall use Commercially Reasonable Efforts to provide the other Party with all reasonable assistance and take all actions reasonably
requested by such other Party, without changing the allocation of responsibilities set forth in this Article 5, that are necessary
or desirable to enable: (a) Oncoheroes to seek, obtain, and maintain Regulatory Approvals for Product in the Licensed Field in the
Territory; and (b) Allarity to seek, obtain, and maintain Regulatory Approvals for Product in the Retained Field in the Territory.
Each Party shall cooperate with any inspection by any Regulatory Authority relating to Product, including any inspection prior to approval
of an application for Regulatory Approval for Product.

 

(b) The
Parties shall share on a timely basis through the JDC (or an applicable subcommittee) significant correspondence to or from a Regulatory
Authority (including submissions of Regulatory Filings) that are relevant to Product. The Parties shall share and review such correspondence
to or from a Regulatory Authority to assure that the Parties provide consistent responses to the Regulatory Authorities with respect
to inquiries relevant to Product. Additionally, to the extent that Allarity prepares a Drug Master File for the Product, then Allarity
shall provide Oncoheroes with a draft of such Drug Master File at least sixty (60) days prior to completion thereof (as well as a final
copy of such Drug Master File upon completion), as well as any modifications or amendments thereto. Oncoheroes shall have the right to
review and comment on any draft of the Drug Master File (as well as any modifications or amendments thereto) and shall provide Allarity
with such comments within thirty (30) days of receipt thereof. Allarity shall consider any such comments in good faith.

 

    22

     

    

 

5.5 Notice
of Regulatory Action. If any Third Party, including a Regulatory Authority, takes or gives notice of its intent to take any regulatory
action with respect to any activity of a Party pursuant to this Agreement, which regulatory action could reasonably be expected to materially
adversely affect any Development, Manufacture, or Commercialization activities with respect to Product in the Licensed Field or in the
Retained Field in the Territory, then such Party shall promptly notify the other Party of such notice or action, and the Parties shall
discuss an appropriate response in good faith.

 

5.6 Remedial
Actions. Each Party shall notify the other immediately, and promptly confirm such notice in writing, if it obtains information indicating
that any Product may be subject to any recall, corrective action, or other regulatory action by any Governmental Authority or Regulatory
Authority (a “Remedial Action”). The Parties shall assist each other in gathering and evaluating such information
as is necessary to determine the necessity of conducting a Remedial Action. Oncoheroes has sole discretion with respect to any matters
relating to any Remedial Action with respect to Product that Oncoheroes, its Affiliates, or its Sublicensees distributed, including the
decision to commence such Remedial Action and the control over such Remedial Action. Allarity has sole discretion with respect to any
matters relating to any Remedial Action with respect to Product that Allarity, its Affiliates, or their licensees (excluding Oncoheroes,
its Affiliates, or its Sublicensees) distributed, including the decision to commence such Remedial Action and the control over such Remedial
Action. Each Party shall bear all costs and expenses of any Remedial Action conducted by it pursuant to this Section 5.6. Each Party
shall, and shall ensure that its Affiliates and Sublicensees or licensees, as applicable, will, maintain adequate records to permit the
Parties to trace the distribution, sale and use of Products in the Territory. Each Party shall provide the other Party, at the other
Party’s expense, with such assistance in connection with a Remedial Action as may be reasonably requested by such other Party.
Notwithstanding the foregoing, any Remedial Action that relates to the Manufacture and supply of Products by Allarity to Oncoheroes is
governed by the terms and conditions of the applicable Supply Agreement and the Novartis Head License Agreement.

 

5.7 Adverse
Event Reporting; SDEA; Global Pharmacovigilance Database.

 

(a) As
between the Parties and in accordance with Section 5.7, : (a) Oncoheroes is responsible for the timely reporting to the appropriate Regulatory
Authorities of all Adverse Events and any other information concerning the safety of Product in the Licensed Field, and (b) Allarity
is responsible for the timely reporting to the appropriate Regulatory Authorities of all Adverse Events and any other information concerning
the safety of Product in the Retained Field. The Party that owns the Regulatory Approval for the applicable Product has the right to
make the final decision with respect to any Adverse Event filing with a Regulatory Authority with respect to such Product in the event
of a dispute and where a decision must be made in order to comply with applicable filing time requirements.

 

    23

     

    

 

(b) Subject
to the terms of this Agreement, and reasonably prior to the Initiation of any Clinical Trial by or on behalf of Oncoheroes, Allarity
and Oncoheroes (under the guidance of their respective pharmacovigilance departments, or equivalent thereof) shall define and finalize
the responsibilities of the Parties to protect patients and promote their well-being in connection with the use of Product pursuant to
a written agreement between the Parties (the “Safety Data Exchange Agreement”). The Safety Data Exchange Agreement
will (a) include mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication, and exchange
(as between the Parties) and regulatory submission of Adverse Event reports, reports of exposure during pregnancy, and any other information
concerning the safety of Product, (b) be in accordance with, and enable the Parties, their Affiliates, and Sublicensees to fulfill, local
and international regulatory reporting obligations to Governmental Authorities, and (c) be consistent with relevant ICH guidelines, except
where said guidelines may conflict with existing local regulatory safety reporting requirements, in which case local reporting requirements
shall prevail. Further, the Safety Data Exchange Agreement will provide for the following: Allarity shall control the global pharmacovigilance
database with respect to Product worldwide.

 

Article
6

COMMERCIALIZATION

 

6.1 Commercialization
Responsibilities.

 

(a) Licensed
Field. Oncoheroes has the exclusive right to conduct, and is solely responsible for all aspects of, the Commercialization of Products
in the Licensed Field in the Territory, including: (a) developing and executing a commercial launch and pre-launch plan, (b) negotiating
with applicable Governmental Authorities regarding the price and reimbursement status of Products; (c) marketing and promotion; (d) booking
sales and distribution and performance of related services; (e) handling all aspects of order processing, invoicing and collection, inventory
and receivables; and (f) providing customer support, including handling medical queries, and performing other related functions, in each
case of (a)–(f) with respect to the Licensed Field; provided, that such decisions are consistent with the express terms
and conditions of this Agreement. As between the Parties, Oncoheroes shall bear all of its costs and expenses incurred in connection
with such Commercialization activities.

 

(b) Retained
Field. Allarity has the exclusive right to conduct, and is solely responsible for all aspects of, the Commercialization of Products
in the Retained Field in the Territory, including: (a) developing and executing a commercial launch and pre-launch plan, (b) negotiating
with applicable Governmental Authorities regarding the price and reimbursement status of Products; (c) marketing and promotion; (d) booking
sales and distribution and performance of related services; (e) handling all aspects of order processing, invoicing and collection, inventory
and receivables; and (f) providing customer support, including handling medical queries, and performing other related functions, in each
case of (a)–(f) with respect to the Retained Field; provided, that such decisions are consistent with the express terms
and conditions of this Agreement. As between the Parties, Allarity shall bear all of its costs and expenses incurred in connection with
such Commercialization activities.

 

6.2 Commercial
Diligence. Oncoheroes shall use Commercially Reasonable Efforts to Commercialize Product for which it has obtained Regulatory Approval.

 

    24

     

    

 

6.3 Standards
of Conduct. Each Party shall perform, and shall ensure that its Affiliates, (sub)licensees and Third Party contractors perform, all
Commercialization activities in a good scientific and ethical business manner and in compliance with Applicable Laws. Oncoheroes and
its Sublicensees (and their respective Affiliates) shall not knowingly promote or sell (or encourage or facilitate the sale of) any Product
for use in the Retained Field. Oncoheroes and its Sublicensees (and their respective Affiliates) shall not provide funding to or otherwise
support continuing education programs for sales representatives or medical professionals in which information is provided about the use
of any Product for use in the Retained Field.Allarity and its licensees (and their respective Affiliates) shall not knowingly promote
or sell (or encourage or facilitate the sale of) any Product for use in the Licensed Field. Allarity shall not provide funding to or
otherwise support continuing education programs for its sales representatives or medical professionals in which information is provided
specifically for the use of any Product in the Licensed Field. Each Party represents that it has established or will establish, and shall
follow, its own internal policies, procedures and standards for promotion, Clinical Trials, Medical Education Activities and other sales
and marketing activities for Products in the Licensed Field(with respect to Oncoheroes) and the Retained Field (with respect to Allarity),
to ensure compliance with Applicable Laws.

 

6.4 Tracking
of Sales of Product.

 

(a) Tracking.
The Parties recognize the possibility that customers or other Third Parties may purchase Product that has received Regulatory Approval
for and is sold for use in the Licensed Field and in the Retained Field. In the case where Product is sold in the Licensed Field and
in the Retained Field in the same country in the Territory, upon the request of either Party, the Parties, through the JDC, shall establish
a process and methodology for the tracking of sales of such Product to determine the extent of sales in each of the Licensed Field and
Retained Field. For this purpose, the Parties through the JDC shall agree on (i) the acquisition of one or more prescription data services
or other relevant market research generally recognized in the pharmaceutical industry as having a high degree of accuracy and reliability
in the tracking of sales of Product attributable to the Licensed Field and the Retained Field (e.g., the IQVIA prescription claims database)
(the “Data Services”), (ii) the methodology for applying any such resulting data and information to the Net Sales
of Product (including use of random sampling, use of data regarding distribution channels as proxy for indication-specific sales and
development of mathematical models for approximating indication-specific sales) (the “Sales Tracking Methodology”),
and (iii) a mechanism for addressing prescriptions that are tracked back to sole source purchasing agreements. All costs associated with
the acquisition and application of such Data Services and Sales Tracking Methodology shall be shared equally by the Parties and specific
details negotiated by the Parties at such a time when necessary.

 

(b) If
the JDC determines that (i) a Product sold by or on behalf of Allarity is actually used for the treatment of indications in the Licensed
Field in a country in the Territory at a level exceeding, on a product-unit sales basis during a Calendar Year, five percent (5%) of
the product unit sales for such Product in the Licensed Field in such Calendar Year period for such country, or (ii) a Product sold by
or on behalf of Oncoheroes is actually used for the treatment of indications in the Retained Field in a country in the Territory at a
level exceeding, on a product-unit sales basis during a Calendar Year, five percent (5%) of the product unit sales for such Product in
the Retained Field in such Calendar Year period for such country, then the Parties shall negotiate in good faith a manner in which a
Party will financially compensate the other Party for such off-label sales.

 

    25

     

    

 

(c) Disputes.
If the JDC cannot agree: (i) on the Data Services and the Sales Tracking Methodology; (ii) on the extent to which sales of Product sold
by or on behalf of Oncoheroes for off-label use in the Retained Field exceeds the applicable five percent (5%) threshold set forth above;
(iii) on the extent to which sales of Product sold by or on behalf of Allarity for off-label use in the Licensed Field exceeds the applicable
five percent (5%) threshold set forth above; or (iv) on the manner in which the Parties are to financially resolve such off-label use;
then, in each case, at the election of either Party, such dispute shall be finally resolved through binding baseball arbitration in accordance
with Section 14.4.

 

Article
7

MANUFACTURING

 

7.1 Supply
Agreement. Oncoheroes shall have the right to obtain from Allarity or, at Oncoheroes’ option, any of Allarity’s contract
manufacturers of Product (each a “CMO”), Product in finished dosage form. Upon Oncoheroes’ request, Allarity
shall negotiate with Oncoheroes, or shall use reasonable efforts to cause the CMO to negotiate with Oncoheroes the terms to be agreed
upon between them, as applicable, of a definitive agreement for the exclusive supply within the Territory of Product (the “Supply
Agreement”). The transfer price for Products by Allarity will equal Allarity’s Cost of Goods to Manufacture or have Manufactured
Product, and Oncoheroes shall have the right to audit Allarity’s books and records to verify the transfer price upon fifteen (15)
days’ notice and at Oncohereos’ sole cost and expense. The Supply Agreement will include supply for all of Oncoheroes’
clinical and commercial requirements for Product.

 

7.2 Quality
Agreement. Together with the Supply Agreement, Oncoheroes and Allarity shall negotiate (or Allarity shall use reasonable efforts
to cause its applicable CMO to negotiate) and enter into a commercially reasonable and customary quality agreement related to the supply
of Product (or component thereof).

 

7.3 Manufacturing
Technology Transfer.

 

(a) If
Oncoheroes elects to obtain supply from CMO under Section 7.1, then Oncoheroes shall be entitled to request and receive from Allarity
all (or a copy of all, as applicable) Licensed Know-How that is reasonably necessary or reasonably useful for the Manufacture of Product,
including, for clarity, the then-current process for the Manufacture of Product (the “Manufacturing Process”), and
Allarity shall provide such support as may be necessary or reasonably useful to Oncoheroes or its designee to use and practice the Manufacturing
Process for the Product, including by assisting Oncoheroes or its designee to enter into agreements with any or all of Allarity’s
CMOs and by waiving any exclusive arrangements Allarity may have with such CMO with respect to the Product. Allarity shall provide all
such Licensed Know-How in such time and in such manner as reasonably agreed by the Parties.

 

    26

     

    

 

(b) Within
sixty (60) days following Oncoheroes’ election of supply from CMO (the “Election Date”), Allarity shall develop
and provide to Oncoheroes a high-level plan describing the steps to be carried out in connection with the transfer of the Manufacturing
Process set forth in Section 7.3(a) (the “Technology Transfer”). The Parties shall then cooperate to complete,
within one hundred twenty (120) days of the Election Date, the preparation of a reasonable implementation plan for a Technology Transfer,
with such plan to include (a) specific timelines and milestones that are consistent with completion of the Technology Transfer within
twelve (12) months (exclusive of any lead time for delivery to Oncoheroes of any equipment of the type used by Allarity or its CMO to
Manufacture the Product) of Oncoheroes’ request, if any, for a Technology Transfer, and (b) a list of all equipment used by Allarity
or its CMO to Manufacture the Product, including a description of Allarity’s source (i.e., whether internally developed or procured
from a Third Party) for each piece of such equipment. The Parties shall memorialize such implementation plan in a writing that is acknowledged
by each Party. Oncoheroes shall use good faith efforts to enable Allarity to obtain its supply of Product from any CMO utilized by Oncoheroes
in the Manufacture of the Product.

 

Article
8

COMPENSATION

 

8.1 Upfront
Payments. Within five (5) Business Days after the Effective Date, Oncoheroes shall pay to Allarity a one-time upfront payment of
[***] Dollars ($[***]).

 

8.2 Development
Milestone Payments. Oncoheroes shall notify Allarity within forty-five (45) days after the first achievement by Oncoheroes or its
Affiliates of the following development milestone events. Oncoheroes shall make the corresponding milestone payment concurrently with
such notice.

 

	Development
Milestone Event
	 	Milestone Payment
	Regulatory Approval of a Product in the U.S.	 	[***] Dollars ($[***])
	Regulatory Approval of a Product in the EU	 	[***] Dollars ($[***])

 

Each
milestone payment is payable one time only, regardless of the number of times the corresponding milestone event is achieved by a Product
and regardless of the number of Products to achieve such milestone event. Under no circumstances shall Oncoheroes be obligated to pay
Allarity more than [***] Dollars ($[***]) in the aggregate pursuant to this Section 8.2.

 

8.3 Royalties.

 

(a) Royalty
Rates. Subject to Sections 8.3(b), 8.3(c) and 8.4, Oncoheroes shall pay to Allarity royalties on aggregate annual Net Sales of all
Products in the Licensed Field in the Territory during the applicable Royalty Term, as calculated by multiplying the applicable royalty
rate below by the corresponding amount of incremental Net Sales of all Products in the Licensed Field in the Territory in each Calendar
Year.

 

    27

     

    

 

	Annual Net Sales of Products in the Territory	 	Royalty Rate	 
	For that portion of annual aggregate Net Sales of Products less than one hundred million Dollars ($100,000,000)	 	[***]	%
	For that portion of annual aggregate Net Sales of Products greater than or equal to one hundred million Dollars ($100,000,000) and less than two hundred million Dollars ($200,000,000)	 	[***]	%
	For that portion of annual aggregate Net Sales of Products greater than or equal to two hundred million Dollars ($200,000,000)	 	[***]	%

 

(b) Royalty
Term. During the Royalty Term, Oncoheroes shall pay royalties under this Section 8.3, on a country-by-country and Product-by-Product
basis, on Net Sales during the period of time beginning on the First Commercial Sale of such Product in such country and continusing
until the expiration of the Royalty Term for such Product in such country.

 

(c) No
Valid Claim. Subject to the last sentence of Section 8.4, during the Royalty Term, on a country-by-country basis, if Product is not
Covered by a Valid Claim of a Licensed Patent or Regulatory Exclusivity in such country, then the royalty rate set forth in Section 8.3(a)
will be reduced by [***] percent ([***]%), effective as of the date such Product is no longer Covered by a Valid Claim of a Licensed
Patent or Regulatory Exclusivity in such country.

 

(d) Royalty
Reports and Payments. Within forty-five (45) days after the end of each Calendar Quarter during the Royalty Term, Oncoheroes shall
deliver to Allarity a written royalty report specifying, on a country-by-country and Product-by-Product basis, the amount of gross sales
and Net Sales of Products during the applicable Calendar Quarter, a calculation of the amount of royalty payment due on such sales for
such Calendar Quarter, any applicable royalty offsets under Section 8.4, and a revised calculation of the payment due after the application
of such offsets. Concurrently with the delivery of such royalty report, Oncoheroes shall pay all royalties due to Allarity with respect
to Net Sales by Oncoheroes, its Affiliates or their respective Sublicensees for each such Calendar Quarter. For clarity, Oncoheroes shall
have no obligation to make royalty reports or payments to Allarity for Net Sales of Product achieved by any Sublicensee, other than as
set forth in Section 8.5.

 

8.4 Third
Party Payments; Floor. If Oncoheroes obtains a license or other rights to any Third Party intellectual property right that is necessary
or reasonably useful to exploit any Product, then, during the Royalty Term, Oncoheroes may deduct from any royalty payments to Allarity
under Section 8.3 [***] percent ([***]%) of any payments otherwise due by Oncoheroes or its Affiliates to Third Parties for any such
license or grant of rights up to a maximum reduction of [***] percent ([***]%) of the royalties due to Allarity for such Calendar Quarter
(and any amounts not otherwise allocated for reduction in such Calendar Quarter may be allocated for reduction in future Calendar Quarters,
subject to this Section 8.4). Notwithstanding anything to the contrary contained in this Agreement, Oncoheroes shall not be entitled
to reduce the royalty payment amounts set forth in Section 8.3(a) below [***] percent ([***]%) of the amounts set forth in Section 8.3(a)
(without giving effect to any other provision of this Agreement).

 

    28

     

    

 

8.5 Sublicense
Income. If Oncoheroes grants a sublicense to one or more Sublicensees under the Licensed Technology, Oncoheroes shall pay to Allarity
[***] percent ([***]%) of any amounts of cash or other consideration received by Oncoheroes or its Affiliates from each such Sublicensee
in consideration for the grant of a sublicense, including upfront fees, milestone payments and royalties within thirty (30) days following
receipt by Oncoheroes from time to time.

 

8.6 Foreign
Exchange. The rate of exchange to be used in computing the amount of currency equivalent in Dollars of Net Sales invoiced in other
currencies shall be the rate used by Oncoheroes in its financial reporting in accordance with Accounting Standards, as applicable.

 

8.7 Manner
and Place of Payment. All payments owed by Oncoheroes under this Agreement shall be made by wire transfer in immediately available
funds to a bank and account designated in writing by Allarity.

 

8.8 Records;
Audits. Oncoheroes and its Affiliates and Sublicensees will maintain complete and accurate records in reasonably sufficient detail
to permit Allarity to confirm the accuracy of the calculation of royalty payments and the achievement of sales milestone events. Upon
reasonable prior notice, such records shall be available during regular business hours for a period of three (3) years from the end of
the Calendar Year to which they pertain for examination, not more often than once each Calendar Year, by an independent certified public
accountant selected by the auditing Party and reasonably acceptable to the audited Party, for the sole purpose of verifying the accuracy
of the financial reports furnished by the other Party pursuant to this Agreement. Any such auditor shall enter into a confidentiality
agreement with the audited Party and shall not disclose the audited Party’s Confidential Information, except to the extent, such
disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments due
by one Party to the other Party under this Agreement. Any amounts shown to be owed but unpaid shall be paid, and any amounts showed to
be overpaid will be refunded, within forty-five (45) days from the accountant’s report. The auditing Party shall bear the full
cost of such audit unless such audit discloses an underpayment or overcharge by the audited Party of more than five percent (5%) of the
amount due, in which case the audited Party shall bear the full cost of such audit.

 

8.9 Taxes.

 

(a) Taxes
on Income. Except as otherwise provided in this Section 8.9, each Party shall be solely responsible for the payment of all taxes
imposed on its share of income arising directly or indirectly from the efforts of the Parties under this Agreement, including taxes asserted
or collected through withholding. In the event of a determination by a tax authority that an amount should have been withheld from a
payment to Allarity (but no such amount was withheld), Allarity shall indemnify Oncoheroes for the withholding tax. Notwithstanding anything
to the contrary in this Agreement, Allarity shall timely pay and be responsible for (and shall indemnify Oncoheroes for) any transfer,
documentary, sales, use, stamp, registration, value added, goods and services tax or other similar tax that is imposed with respect to
the transactions, payments or the related transfer of rights or other property pursuant to the terms of this Agreement. Oncoheroes shall
be entitled to offset any taxes for which Oncoheroes is indemnified pursuant to this Section 8.9 from amounts otherwise owed to Allarity
under this Agreement.

 

    29

     

    

 

(b) Withholding
Tax. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding or similar
obligations in respect of royalties, milestone payments, and other payments made by Oncoheroes to Allarity under this Agreement. To the
extent Oncoheroes is required to deduct and withhold taxes on any payment to Allarity, Oncoheroes shall pay the amounts of such taxes
to the proper Governmental Authority in a timely manner and promptly transmit to Allarity an official tax certificate or other evidence
of such withholding sufficient to enable Allarity to claim such payment of taxes. Any such amounts deducted or withheld by Oncoheroes
shall be treated as having been paid to Allarity for purposes of this Agreement. On or prior to the Effective Date, Allarity shall deliver
to Oncoheroes a properly completed Internal Revenue Service Form W-8BEN-E. Each Party shall provide the other with reasonable assistance
to enable the recovery, as permitted by applicable Laws, of withholding taxes, value added taxes, or similar obligations resulting from
payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax.

 

8.10 Existing
Upstream Licenses. Allarity agrees that all upfront, milestone, royalty, and other payments to any Third Party with respect to any
Upstream License, including those listed on Exhibit 1.91, will be the responsibility of Allarity, and Allarity will pay all such
amounts as due under each such Upstream License.

 

Article
9

INTELLECTUAL PROPERTY MATTERS

 

9.1 Ownership
of Inventions.

 

(a) Inventions.
Each Party owns all rights, title, and interests in and to any and all Know-How or Inventions made solely by or on behalf of such Party
or its Affiliates in connection with the performance of such Party’s activities under this Agreement and any Patents claiming any
such Know-How or Inventions. The Parties jointly own any and all Joint Inventions and Joint Patents. All determinations of inventorship
under this Agreement will be made in accordance with U.S. patent law.

 

(b) Disclosure.
(i) Each Party shall promptly disclose to the other Party all Inventions, and (ii) each Party shall promptly disclose to the other Party
all Joint Inventions, in each case ((i) of (ii)), prior to the filing of any patent application with respect to such Inventions, including
all invention disclosures or other similar documents submitted to such Party by its or its Affiliates’ employees, agents, or independent
contractors relating thereto. Each Party shall also promptly respond to reasonable requests from the other Party for additional information
relating thereto.

 

(c) Licenses.
Oncoheroes shall and hereby does grant to Allarity a royalty-free, fully paid-up, exclusive (even as to Oncoheroes and its Affiliates),
perpetual, irrevocable license (with the right to grant sublicenses through multiple tiers) under Oncoheroes Inventions to research,
Develop, make, have made, use, sell, have sold, offer for sale, import, and otherwise Commercialize Product in the Retained Field in
the Territory, subject to the terms and conditions of this Agreement.

 

    30

     

    

 

9.2 Patent
Prosecution and Maintenance. For purposes of this Section 9.2, the terms “prosecution” and “maintenance”
(including variations such as “prosecute” and “maintain”) means, with respect to a Patent, the preparation, filing,
prosecution (including conducting all correspondence and interactions with any patent office and seeking, conducting and defending all
any interferences, inter partes reviews, reissue proceedings, reexaminations, and oppositions and similar proceedings) and maintenance
(including payment of any patent annuity fees) of such Patent, as well as re-examinations, reissues, appeals, post grant reviews (PGR),
inter partes reviews (IPR) and requests for patent term adjustments, patent term extensions, supplementary protection certificates, or
their equivalents with respect to such Patent, together with the initiation or defense of interferences, oppositions and other similar
proceedings with respect to the particular Patent, and any appeals therefrom. For clarity, “prosecution” and “maintenance”
(including variations such as “prosecute” and “maintain”) exclude any enforcement action with respect to a Patent.

 

(a) Prosecution
of Licensed Patents. Allarity has the first right, but not the obligation, to prosecute and maintain the Licensed Patents (other
than Joint Patents, which are addressed in Section 9.2(b)) in the Territory using counsel of its own choice, at Allarity’s
sole expense. Allarity shall keep Oncoheroes reasonably informed of progress with respect to the prosecution and maintenance of such
Licensed Patents in the Territory. In addition, Allarity shall provide Oncoheroes with drafts of all proposed substantive filings and
correspondence to any patent authority with respect to any Licensed Patent for Oncoheroes’ review and comment prior to the submission
of such proposed filings and correspondence. Allarity shall consider in good faith Oncoheroes’ comments related to such Licensed
Patent prior to submitting such filings and correspondence. If Allarity decides to abandon any Licensed Patent in its entirety, Oncoheroes
may assume Allarity’s rights and responsibilities under this Section 9.2(a) with respect to such Licensed Patent. Oncoheroes
will thereafter be responsible for the prosecution and maintenance of such Licensed Patent.

 

(b) Joint
Patents. The Parties shall establish the patent strategy for the prosecution and maintenance of any Joint Patents, and shall determine,
on an Invention-by-Invention basis, which Party shall be responsible for the prosecution and maintenance of such Patents (such Party,
the “Prosecuting Party”). In determining the Prosecuting Party, the Parties shall take into account each Party’s
intellectual property or Patent position with respect to the relevant Invention. The Prosecuting Party shall keep the other Party reasonably
informed of progress with regard to its prosecution and maintenance of any Patents described in this Section 9.2(b), including by
providing such other Party with drafts of all proposed substantive filings and correspondence to any relevant patent authority for such
other Party’s review and comment prior to the submission of such proposed filings and correspondence. The Prosecuting Party shall
consider in good faith the other Party’s comments related to such Patents prior to submitting such filings and correspondence,
provided that the other Party provides such comments to the Prosecuting Party within thirty (30) days (or a shorter period reasonably
designated by the Prosecuting Party if thirty (30) days is not practicable given the filing deadline) of receiving the draft filings
and correspondence from the Prosecuting Party. If the Prosecuting Party seeks to abandon or cease the prosecution or maintenance of any
Patent described in this Section 9.2(b) (without initiation of the prosecution and maintenance of a substitution therefor), then the
Prosecuting Party shall provide reasonable prior written notice to the other Party of such intention to abandon or cease such prosecution
or maintenance (which notice shall be given no later than thirty (30) days prior to the next deadline for any action that must be
taken with respect to any such Joint Patent with the patent office). In such case, at the other Party’s sole discretion, upon written
notice to the Prosecuting Party, such other Party may elect to continue the prosecution and maintenance of any such Patent described
in this Section 9.2(b), and will thereafter be the Prosecuting Party with respect to such Joint Patent. The Parties shall mutually agree
on the percentage of expenses that each Party shall bear with respect to the prosecution of Joint Patents (which in the absence of any
other agreement between the Parties shall be borne by the Prosecuting Party).

 

    31

     

    

 

(c) Cooperation
of the Parties. Each Party shall cooperate fully in the preparation, filing, prosecution and maintenance of the Licensed Patents
and Joint Patents pursuant to this Section 9.2. Such cooperation includes (a) executing all papers and instruments, or requiring
its employees or contractors, to execute such papers and instruments, so as to effectuate the ownership of Inventions as set forth in
Section 9.1, and Patents claiming or disclosing such Inventions, and as to enable the other Party to apply for and to prosecute
patent applications in any country as permitted by Section 9.2, and (b) promptly informing the other Party of any matters coming
to such Party’s attention that may affect the prosecution and maintenance of any such patent applications.

 

9.3 Enforcement.

 

(a) Notice;
Procedures. Each Party shall notify the other Party within ten (10) Business Days of becoming aware of any alleged or threatened
infringement by a Third Party of (i) Joint Patents anywhere in the world or (ii) Licensed Patents (other than Joint Patents) if infringement
of such Licensed Patents adversely affects or is expected to adversely affect any Product the Territory, and in each case of (i) and
(ii), any related declaratory judgment or equivalent action alleging the invalidity, unenforceability or non-infringement of such Patents
(collectively “Infringement”). For clarity, any Infringement excludes those adversarial proceedings that are addressed
in Section 9.2.

 

(b) Enforcement
Rights.

 

(i) Licensed
Patents. As between the Parties, Oncoheroes has the first right, but not the obligation, to bring and control any legal action to
enforce any Licensed Patents against any Infringement in the Licensed Field in the Territory, at its own expense as it reasonably determines
appropriate, and Oncoheroes shall consider in good faith the interests of Allarity in such enforcement of any such Patents. If Oncoheroes
or its designee fails to file an action to abate such Infringement within ninety (90) days after a written request from Allarity to do
so, or if Oncoheroes discontinues the prosecution of any such action after filing without abating such infringement, then if such Infringement
has not otherwise been abated by Oncoheroes or its designee, Allarity may enforce any Licensed Patent against the relevant Infringement
in the Territory, at its own expense as it reasonably determines appropriate, provided that Oncoheroes does not provide reasonable rationale
for not doing so or continuing to do so (including a substantive concern regarding counter-claims by the infringing Third Party).

 

(ii) Joint
Patents. If either Party becomes aware of any alleged or threatened Infringement by a Third Party of any Joint Patent, then such
Party shall so notify the other Party, and the Parties shall promptly confer and determine (1) whether to bring such an enforcement action
against such Third Party, (2) the strategy to be employed in connection with any such action, or (3) the manner in which to settle such
action. Unless otherwise agreed, Oncoheroes has the first right, but not the obligation, to bring and control any legal action to enforce
any Joint Patents against any Infringement in the Licensed Field, at its own expense as it reasonably determines appropriate, and Oncoheroes
shall consider in good faith the interests of Allarity in such enforcement of any such Patents. Unless otherwise agreed, if Oncoheroes
or its designee fails to file an action to abate such Infringement within ninety (90) days after a written request from Allarity to do
so, or if Oncoheroes discontinues the prosecution of any such action after filing without abating such infringement, then if such Infringement
has not otherwise been abated by Oncoheroes or its designee, Allarity may enforce any Joint Patent against the relevant Infringement,
at its own expense as it reasonably determines appropriate, provided that Oncoheroes does not provide reasonable rationale for not doing
so or continuing to do so (including a substantive concern regarding counter-claims by the infringing Third Party). The Party not bringing
an action under this Section 9.3(b)(ii) will be entitled to separate representation in such proceeding by counsel of its own choice and
at its own expense and will cooperate fully with the Party bringing such action. Notwithstanding the foregoing, each Party shall discuss
any such action it intends to bring under this Section 9.3(b)(ii) with the other Party, and shall not take any substantive position in
any such enforcement proceeding or take any action in such enforcement proceeding that such Party reasonably believes in good faith would
have the potential to adversely affect or limit the scope, validity, or enforceability of any claim in any Patent Controlled by such
Party or its Affiliate that relates to Product.

 

    32

     

    

 

(c) Cooperation.
If a Party brings an infringement action in accordance with this Section 9.3 (such Party, the “Enforcing Party”),
the other Party shall cooperate fully, including, if required to bring such action, furnishing a power of attorney or being named as
a party to such infringement action. The Enforcing Party shall not enter into any settlement or compromise of any action under this Section 9.3:
(i) in a manner that would diminish the rights or interests of the other Party without the written consent of such other Party,
not be unreasonably withheld, conditioned, or delayed; or (ii) that would impose any cost or liability on the other Party, or admit
the invalidity or unenforceability of any Patent Controlled by the other Party, without such other Party’s prior written consent,
which may be withheld in such other Party’s sole discretion.

 

(d) Recovery.
Except as otherwise agreed by the Parties in connection with a cost-sharing arrangement, any recovery as a result of any action or proceeding
pursuant to Section 9.3(b), whether by way of settlement or otherwise, will be first used to reimburse the Enforcing Party for its
documented, out-of-pocket costs and expenses (including court, attorneys’ and professional fees) incurred in connection with such
action or proceeding, and then to reimburse the other Party for its documented, out-of-pocket costs and expenses (including court, attorneys’
and professional fees) incurred in connection with such action or proceeding (to the extent not previously reimbursed by the Enforcing
Party), and any remainder of the recovery after reimbursement of the litigation costs and expenses of the Parties, will be shared seventy-five
percent (75%) to the Enforcing Party and twenty-five percent (25%) to the non-Enforcing Party.

 

9.4 Infringement
of Third-Party Rights. Each Party shall promptly notify the other in writing of any allegation by a Third Party that Manufacture,
use or sale of Product infringes or may infringe the intellectual property rights of such Third Party. Except as otherwise provided in
Article 11, (a) Oncoheroes has the sole right to control any defense of any such claim involving alleged infringement of Third Party
rights by Oncoheroes’ activities at its own expense and by counsel of its own choice, and Allarity may, at its own expense, be
represented in any such action by counsel of its own choice if such intellectual property rights pertain to the Territory and (b) Allarity
has the sole right to control any defense of any such claim involving alleged infringement of Third Party rights by Allarity’s
activities at its own expense and by counsel of its own choice, and Oncoheroes may, at its own expense, be represented in any such action
by counsel of its own choice. Except as otherwise provided in Article 11, neither Party may settle any patent infringement litigation
under this Section 9.4 in a manner that diminishes the rights or interests of the other Party without the written consent of such
other Party (which shall not be unreasonably withheld, conditioned, or delayed).

 

9.5 Patent
Term Extensions. Allarity will cooperate with Oncoheroes, at Oncoheroes’ request, in seeking and obtaining patent term extensions
(including any pediatric exclusivity extensions as may be available) or supplemental protection certificates or their equivalents in
any country with respect to any Licensed Patents and Products. If elections with respect to obtaining such patent term extensions are
to be made, Oncoheroes shall have the right to make such elections with respect to the Product with Allarity’s prior written consent.

 

9.6 Trademarks.

 

(a) Product
Marks. Oncoheroes may brand Product in the Licensed Field in the Territory using trademarks, logos, and trade names it determines
appropriate (the “Product Marks”). Oncoheroes owns all rights in the Product Marks and shall register and maintain
the Product Marks that it determines reasonably necessary, at Oncoheroes’ cost and expense.

 

(b) Licensed
Marks. As between the Parties, Allarity owns and retains all right, title, and interest in and to all trademarks associated with
any trademarks Controlled by Allarity that are associated solely with Products (each, a “Licensed Mark”). Allarity
shall register and maintain all Licensed Marks at Allarity’s cost and expense, and all goodwill in any such Licensed Mark shall
accrue to Allarity. Allarity hereby grants Oncoheroes an exclusive (even as to Allarity), fully paid-up, royalty-free, sublicensable
license to use the Licensed Marks in connection with the Commercialization of the Products in the Licensed Field in the Territory in
accordance with Allarity’s trademark usage policies that it may make available to Oncoheroes from time to time.

 

(c) Corporate
Marks. Notwithstanding anything to the contrary, to the extent required by Applicable Law, (i) Oncoheroes may include Allarity’s
name and corporate logo on the Product label, packaging, promotional/marketing materials to indicate that the Product is in-licensed
from Allarity, and (ii) Allarity hereby grants to Oncoheroes a non-exclusive, fully paid-up, royalty free, sublicensable license to use
Allarity’s name and corporate logo for the Commercialization of Product in the Territory to the extent consistent with this Section
9.6(c) and in accordance with Allarity’s trademark and corporate mark usage policies that it may make available to Oncoheroes from
time to time.

 

    33

     

    

 

Article
10

REPRESENTATIONS AND WARRANTIES; COVENANTS

 

10.1 Mutual
Representations and Warranties. Each Party represents and warrants to the other Party, as of the Effective Date, that: (a) it
is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other
power and authority to enter into this Agreement and to carry out the provisions hereof; (b) it is duly authorized to execute and
deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has
been duly authorized to do so by all requisite corporate or partnership action; and (c) this Agreement is legally binding upon it,
enforceable in accordance with its terms, and does not conflict with any agreement, instrument or understanding, oral or written, to
which it is a Party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative
or other agency having jurisdiction over it.

 

10.2 Allarity
Representations and Warranties. Allarity hereby represents and warrants to Oncoheroes as follows, as of the Effective Date:

 

(a) Existing
Patents. Exhibit 1.60 attached hereto contains a true and complete list of the existing Licensed Patents as of the Effective
Date (the “Existing Patents”);

 

(b) Title;
Encumbrances. Allarity is the sole owner of the entire right, title and interest in and to all Patents and other intellectual property
rights within the Licensed Technology, free and clear from any mortgages, pledges, liens, security interests, conditional and installment
sale agreements, encumbrances, charges or claims of any kind. Allarity has the full and legal rights and authority to grant all rights
and licenses it purports to grant to Oncoheroes under this Agreement;

 

(c) Control.
Allarity Controls (i) all Patents owned, invented or licensed by Allarity that are necessary or useful for the research, Development,
Manufacture, use, offer for sale, sale or import of the Product, and (ii) all Know-How owned, generated or licensed by Allarity
that is related to the Product;

 

(d) Licensed
Patents. All maintenance fees, annuity payments, and similar payments relating to the Licensed Patents have been made by Allarity
in a timely manner. Allarity has not taken action or failed to undertake any action in connection with the filing, prosecuting and maintaining
the Licensed Patents in violation of any Applicable Law. Allarity does not have knowledge of any Information which leads it to believe
that any issued Patents in the Licensed Patents are invalid or unenforceable;

 

(e) No
Infringement. No claim or action has been brought or, to Allarity’s knowledge, threatened by any Third Party alleging that
the use of the Licensed Technology, or the Development, Manufacture, or Commercialization of the Product (whether by Allarity prior to
the Effective Date or as anticipated hereunder), infringes or misappropriates, or would infringe or misappropriate, any published or
issued Patent or other intellectual property right of any Third Party, and no facts or circumstances exist, to Allarity’s knowledge,
that would reasonably be expected to give rise to any such claims. To Allarity’s knowledge, the Development, Manufacture, and Commercialization
of the Product can be carried out in a manner anticipated hereunder without infringing any Third Party’s published or issued Patent
or other intellectual property rights;

 

    34

     

    

 

(f) No
Conflicts. Allarity has not entered into any agreement with any Third Party that is in conflict or inconsistent with the rights granted
to Oncoheroes under this Agreement or would impede the performance of its obligations hereunder, and has not taken any action that would
in any way prevent it from granting the rights granted to Oncoheroes under this Agreement, or that would otherwise conflict with or adversely
affect Oncoheroes’ rights under this Agreement, or that would impede its performance of its obligations hereunder;

 

(g) Intellectual
Property Rights. The Licensed Technology includes all intellectual property rights Controlled by Allarity that are reasonably necessary
or useful for the Development and Commercialization of the Product by Oncoheroes in accordance with the terms of this Agreement.

 

(h) Third
Party Technology. To Allarity’s knowledge, there are no pending Third Party patent applications that, if issued with the published
or currently pending claims, would be infringed by the Development, Manufacture, or Commercialization of Products;

 

(i) Third
Party Infringement. To Allarity’s knowledge, no Third Party is infringing or has infringed any Licensed Patents or has misappropriated
any Licensed Know-How;

 

(j) No
Proceeding. There are no pending and, to Allarity’s knowledge, no threatened, adverse actions, suits or proceedings (including
Patent interferences, reissues, reexaminations, cancellations, oppositions, nullity actions, invalidation actions or post-grant reviews)
against Allarity involving the Licensed Technology or Products or challenging Allarity’s ownership rights in, or the validity or
scope of any Licensed Patent;

 

(k) Regulatory
Actions.

 

(i) Allarity
has not received any written communications from any Regulatory Authority describing any matters specific to a Product, or to any class
of drugs to which a Product belongs, that may be necessary to be overcome in order to obtain Regulatory Approval of any Product, nor
does Allarity have any knowledge of any basis for such matters;

 

(ii) All
Regulatory Filings by Allarity with respect to the Product, to Allarity’s knowledge, were, at the time of filing, true, complete,
and accurate;

 

(iii) Allarity
and its Affiliates are not, and have not been, debarred or disqualified by any Regulatory Authority;

 

(iv) Allarity
has filed with the applicable Regulatory Authority all required notices, reports, and other Regulatory Filings with respect to each IND
held by Allarity for the Product; and

 

(v) Allarity
has not received any notice from any Regulatory Authority or other governmental authority commencing or threatening withdrawal of any
active IND held by Allarity.

 

    35

     

    

 

(l) Clinical
Data. Allarity is the sole owner of all rights to the clinical data generated in the performance of the Allarity’s Development
of the Product prior to the Effective Date.

 

(m) Compliance
with Laws. All Development of the Product conducted by or on behalf of Allarity prior to the Effective Date has been conducted in
compliance with all Applicable Laws and all Product used in all clinical studies conducted by or on behalf of Allarity has been Manufactured
in compliance with GMP;

 

(n) No
Litigation. Allarity is not a party to any legal action, suit or proceeding relating to the Product in the Licensed Field or in the
Retained Field in the Territory;

 

(o) No
Debarment. Neither Allarity nor any of its Affiliates is or has been debarred or suspended under 21 U.S.C. §335(a) or §335(b)
or any foreign equivalent thereof, or is the subject of a conviction described in such section or any foreign equivalent thereof;

 

(p) Compliance.
There are no legal claims, judgments or settlements against or owed by Allarity or any of its Affiliates, or pending or, to Allarity’s
knowledge, threatened, legal claims or litigation, in each case, relating to antitrust, anti-competition, anti-bribery or corruption
violations;

 

(q) Disclosure.
To Allarity’s knowledge: (i) Allarity has disclosed to Oncoheroes all material written information in Allarity’s possession
or Control as of the Effective Date relating to Products, and all such information disclosed by Allarity is true, complete, and correct;
and (ii) there are no issues or information related to the Licensed Technology or otherwise which are reasonably likely to have a material
or adverse impact on the Development, Manufacture, or Commercialization of the Product that have not been fully disclosed to Oncoheroes;
and

 

(r) Upstream
Licenses. The Upstream Licenses set forth on Exhibit 1.91 constitute all agreements pursuant to which Allarity or its Affiliates
Control any Know-How or Patents that are necessary or reasonably useful to Develop, use, make, have made, sell, offer for sale, have
sold, import, and otherwise Commercialize the Products in the Licensed Field in the Territory. Neither Allarity nor any of its Affiliates
is in breach of an existing Upstream License, nor have they received or given any written notice of default or termination under any
existing Upstream License. To the knowledge of Allarity, Allarity and its Affiliates have not performed or omitted to perform any act
that would provide a right to terminate any Upstream License.

 

10.3 Representations
and Warranties of Oncoheroes. Oncoheroes represents and warrants to Allarity that as of the Effective Date:

 

(a) Oncoheroes
and its Affiliates are not, and have not been, debarred or disqualified by any Regulatory Authority;

 

(b) Oncoheroes
has sufficient financial wherewithal to (i) perform all of its obligations pursuant to this Agreement, and (ii) meet all of its obligations
that come due in the ordinary course of business;

 

    36

     

    

 

(c) Oncoheroes
has, or can readily obtain, sufficient technical, clinical, and regulatory expertise to perform all of its obligations pursuant to this
Agreement, including its obligations relating to the Products in the Licensed Field in the Territory; and

 

(d) Oncoheroes
has obtained from its employees, agents and Affiliates enforceable assignments that assign the Oncoheroes Inventions, without limitation,
to Oncoheroes and Oncoheroes has recorded such assignments where necessary in accordance with Applicable Laws.

 

10.4 Allarity
Covenants. Allarity hereby covenants to Oncoheroes as follows:

 

(a) Control.
Allarity shall Control throughout the Term (i) all Patents owned, invented or licensed by Allarity that are necessary or useful for the
research, Development, Manufacture, use, offer for sale, sale or import of the Product, and (ii) all Know-How owned, generated or
licensed by Allarity that is related to the Product; and

 

(b) No
Conflicts. Allarity shall not enter into any agreement with any Third Party that is in conflict with the rights granted to Oncoheroes
under this Agreement or would impede the performance of its obligations hereunder, and shall not take any action that would in any way
prevent it from granting the rights granted to Oncoheroes under this Agreement, or that would otherwise conflict with or adversely affect
Oncoheroes’ rights under this Agreement, or would impede its performance of its obligations hereunder.

 

(c) No
Breach. With respect to any Upstream License: (a) Allarity will not breach any such agreement in a manner that would give rise to
the right of any Third Party to terminate such agreement; (b) Allarity will promptly notify Oncoheroes of any such breach by Allarity
or a Third Party of any such agreement, in each case, of which Allarity is aware; and (c) in the event of any such breach by Allarity
that is not cured within sixty (60) days after written notice to Oncoheroes, (i) Allarity will permit Oncoheroes to cure such breach
on Allarity’s behalf upon Oncoheroes’ reasonable written request, and (ii) Oncoheroes may offset any reasonable amounts paid
to cure such breach against amounts otherwise payable by Oncoheroes to Allarity under this Agreement; and

 

(d) No
Amendment. Allarity will not amend, modify or terminate any Upstream License in a manner that would adversely affect Oncoheroes’
rights or licenses under this Agreement, without first obtaining Oncoheroes’ written consent, which consent may be withheld in
Oncoheroes’ sole discretion.

 

10.5 Mutual
Covenants.

 

(a) No
Debarment. In the course of Development by of the Product, neither Party shall use any employee or consultant who has been debarred
by any Regulatory Authority or, to such Party’s knowledge, is the subject of debarment proceedings by a Regulatory Authority. Each
Party shall notify the other Party promptly upon becoming aware that any of its employees or consultants has been debarred or is the
subject of debarment proceedings by any Regulatory Authority.

 

    37

     

    

 

(b) Compliance.

 

(i) Each
Party and its Affiliates shall comply in all material respects with all Applicable Laws in the Development, Manufacture, and Commercialization
of Products and performance of its obligations under this Agreement, including, to the extent applicable to such Party and its activities
hereunder, the statutes, regulations and written directives of the FDA, the EMA and any Regulatory Authority having jurisdiction in the
Territory, the FD&C Act, the Prescription Drug Marketing Act, the Federal Health Care Programs Anti-Kickback Law, 42 U.S.C. 1320a-7b(b),
the statutes, regulations and written directives of Medicare, Medicaid and all other health care programs, as defined in 42 U.S.C. §
1320a-7b(f), as each as may be amended from time to time.

 

(ii) Without
limiting the foregoing, each Party shall comply with Anti-Corruption Laws, and shall not cause the other Party or its Affiliates, directors,
officers, shareholders, employees or agents to be in violation of any Anti-Corruption Laws. Without limiting the foregoing, neither Party
shall, directly or indirectly, pay any money to, or offer or give anything of value to, any “foreign official” as that term
is used in the FCPA or any “foreign public official” as that term is used in the FCPA, in order to obtain or retain business
or to secure any commercial or financial advantage for the other Party or for itself or any of their respective Affiliates or Sublicensees.
Each Party understands that if it fails to comply with the provisions of Anti-Corruption Laws, then such failure shall automatically
be deemed a breach that allows the other Party to terminate this Agreement in accordance with Section 13.3, provided that, the other
Party will in such case not have to allow the infringing Party any notice period or cure period.

 

10.6 Disclaimer.
EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER,
WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION
OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY, AND ALL REPRESENTATIONS AND WARRANTIES, WHETHER
ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. Each
party acknowledges and agrees that the other party has not made any representations, express or implied with respect to the subject matter
of this Agreement, other than those contained in this agreement.

 

Article
11

INDEMNIFICATION

 

11.1 By
Oncoheroes. Oncoheroes shall and hereby does save, defend and hold Allarity and its Affiliates and their respective directors, officers,
employees and agents (each, a “Allarity Indemnitee”) harmless from and against any and all claims, suits, actions,
demands, liabilities, expenses and loss, including reasonable legal expense and attorneys’ fees (collectively, “Losses”)
to which any Allarity Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party to
the extent such Losses arise directly or indirectly out of: (a) the research, Development, Manufacture, use, marketing, promotion, distribution,
handling, storage, sale or other disposition of Product by or on behalf of Oncoheroes or any of its Affiliates or Sublicensees; (b) the
breach by Oncoheroes of any provision of this Agreement; or (c) the gross negligence or willful misconduct of any Oncoheroes Indemnitee;
except, in each case, to the extent such Losses result from the gross negligence or willful misconduct of any Allarity Indemnitee or
the breach by Allarity of any provision of this Agreement.

 

    38

     

    

 

11.2 By
Allarity. Allarity shall and hereby does save, defend and hold Oncoheroes and its Affiliates and their respective directors, officers,
employees and agents (each, an “Oncoheroes Indemnitee”) harmless from and against any and all Losses to which any
Oncoheroes Indemnitee may become subject as a result of any claim, demand, action or other proceeding by any Third Party to the extent
such Losses arise directly or indirectly out of: (a) the research, Development, Manufacture, use, marketing, promotion, distribution,
handling, storage, sale or other disposition of Product by or on behalf of Allarity or any of its Affiliates or licensees (other than
Oncoheroes), (b) the breach by Allarity of any provision of this Agreement, including Allarity’s obligations with respect
to taxes pursuant to Section 8.9 and for purposes of this Section 11.2, “Losses” includes taxes; or (c) the gross
negligence or willful misconduct of any Allarity Indemnitee; except, in each case, to the extent such Losses result from the gross negligence
or willful misconduct of any Oncoheroes Indemnitee or the breach by Oncoheroes of any provision of this Agreement.

 

11.3 Procedure.
If a Party (the “Indemnified Party”) seeks indemnification under Section 11.1 or 11.2, the Indemnified Party
shall: (a) inform the other Party (the “Indemnifying Party”) of a claim as soon as reasonably practicable after
it receives notice of the claim (it being understood and agreed, however, that the failure by an Indemnified Party to give notice of
a claim as provided in this Section 11.3 shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement
except and only to the extent that such Indemnifying Party is actually and materially damaged as a result of such failure to give notice);
(b) permit the Indemnifying Party to assume direction and control of the defense of the claim (including the right to settle the claim
solely for monetary consideration) using counsel reasonably satisfactory to the Indemnified Party so long as (I) such claim solely involves
monetary consideration and (II) the Indemnifying Party agrees (as between the Parties) to assume sole responsibility for such claim;
and (c) cooperate as requested (at the expense of the Indemnifying Party) in the defense of the claim. If the Indemnifying Party
does not assume control of such defense within fifteen (15) days after receiving notice of the claim from the Indemnified Party, the
Indemnified Party shall control such defense and, without limiting the Indemnifying Party’s indemnification obligations, the Indemnifying
Party shall reimburse the Indemnified Party for all costs, including reasonable attorney fees, incurred by the Indemnified Party in defending
itself within thirty (30) days after receipt of any invoice therefor from the Indemnified Party. The Party not controlling such defense
may participate therein at its own expense. The Party controlling such defense shall keep the other Party advised of the status of such
action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto.
The Indemnified Party shall not agree to any settlement of such action, suit, proceeding or claim without the prior written consent of
the Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned. The Indemnifying Party shall not agree to any
settlement of such action, suit, proceeding or claim or consent to any judgment in respect thereof that does not include a complete and
unconditional release of the Indemnified Party from all liability with respect thereto, that imposes any liability or obligation on the
Indemnified Party or that acknowledges fault by the Indemnified Party without the prior written consent of the Indemnified Party.

 

    39

     

    

 

11.4 Insurance.
Each Party, at its own expense, shall maintain product liability and other appropriate insurance (or self-insure) in an amount consistent
with industry standards during the Term. Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing
such coverage to the other Party upon request.

 

11.5 Limitation
of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES
ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING
THE FOREGOING, NOTHING IN THIS SECTION 11.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT (A) THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF
ANY PARTY UNDER SECTION 11.1 OR 11.2 SOLELY WITH RESPECT TO CLAIMS BY THIRD PARTIES, OR (B) DAMAGES AVAILABLE FOR A PARTY’S
BREACH OF ITS CONFIDENTIALITY AND NON-USE OBLIGATIONS UNDER ARTICLE 12.

 

Article
12

CONFIDENTIALITY

 

12.1 Confidential
Information. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, each Party
agrees that, during the Term and for ten (10) years thereafter, such Party (the “Receiving Party”) shall keep confidential
and shall not publish or otherwise disclose and shall not use for any purpose, other than as expressly provided for in this Agreement,
any Confidential Information furnished to it by or on behalf of the other Party (the “Disclosing Party”). The Receiving
Party may use Confidential Information only to the extent required to accomplish the purposes of this Agreement. The Receiving Party
shall use at least the same standard of care as it uses to protect proprietary or confidential information of its own, but no less than
reasonable care, to ensure that its, and its Affiliates’ and Sublicensees’, employees, agents, consultants and other representatives
(“Representatives”) do not disclose or make any unauthorized use of the Confidential Information. The Receiving Party
will promptly notify the Disclosing Party upon discovery of any unauthorized use or disclosure of the Confidential Information.

 

12.2 Exceptions.
Confidential Information shall not include any information that the Receiving Party can prove by competent evidence: (a) is now,
or hereafter becomes, through no act or failure to act on the part of the Receiving Party in breach of this Agreement, generally known
or available to the public; (b) is known by the Receiving Party at the time of receiving such information, as evidenced by its records;
(c) is hereafter furnished to the Receiving Party on a non-confidential basis by a Third Party, as a matter of right (i.e.,
without breaching any obligation such Third Party may have to the Disclosing Party); or (d) is independently discovered or developed
by the Receiving Party, independently of the activities undertaken by the Receiving Party pursuant to this Agreement and without the
use of Confidential Information of the Disclosing Party, as evidenced by the Receiving Party’s contemporaneously-maintained written
records.

 

12.3 Authorized
Disclosure. Each Party may disclose Confidential Information of the other Party as expressly permitted by this Agreement, or if and
to the extent such disclosure is necessary in the following instances:

 

(a) filing
or prosecuting Patents as permitted by this Agreement;

 

    40

     

    

 

(b) enforcing
such Party’s rights under this Agreement and performing its obligations under this Agreement;

 

(c) prosecuting
or defending litigation as permitted by this Agreement;

 

(d) complying
with applicable court orders or applicable laws, rules and regulations, or the listing rules of any exchange on which such Party’s
securities are traded;

 

(e) in
Regulatory Filings that the Receiving Party has the right to file, or holds, as expressly set forth in this Agreement;

 

(f) disclosure
to the Receiving Party’s Affiliates, licensees and sublicensees/Sublicensees, potential licensees and sublicensees/Sublicensees,
and to the Receiving Party’s and its Affiliates’ Representatives who, in each case, need to know such information in order
for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement, provided, in each case, that any such
Affiliate, actual or potential licensee or sublicensee/Sublicensee, or Representative agrees to be bound by terms of confidentiality
and non-use at least as restrictive as those set forth in this Article 12; and

 

(g) disclosure
to Third Parties in connection with due diligence or similar investigations by such Third Parties, and disclosure to potential Third-Party
investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be bound by reasonable obligations
of confidentiality and non-use.

 

Notwithstanding
the foregoing, if the Receiving Party is required to make a disclosure of the Disclosing Party’s Confidential Information pursuant
to Section 12.3(c) or 12.3(d), it will, except where impracticable, (i) give reasonable advance notice to the Disclosing Party
of such disclosure, (ii) use efforts to secure confidential treatment of such information at least as diligent as the Receiving
Party would use to protect its own confidential information, but in no event less than reasonable efforts, and (iii) cooperate with
any efforts by the Disclosing Party, at the Disclosing Party’s request and expense, to secure confidential treatment of such Confidential
Information. Disclosure by the Receiving Party of Confidential Information in accordance with any of the foregoing provisions of this
Section 12.3 shall not, in and of itself, cause the information so disclosed to cease to be treated as Confidential Information
under this Agreement, except to the extent that, by virtue of disclosure by the Receiving Party in full compliance with this Section 12.3,
such information becomes generally known or available.

 

12.4 Confidentiality
of this Agreement. Except as otherwise provided in this Article 12 each Party agrees not to disclose to any Third Party the terms
of this Agreement without the prior written consent of the other Party hereto, except that each Party may disclose the terms of this
Agreement that are otherwise made public as contemplated by Section 12.5 or to the extent such disclosure is permitted under Section 12.3.

 

    41

     

    

 

12.5 Public
Announcements.

 

(a) The
Parties shall agree on the content and form of the expected press release from each Party and shall coordinate to the extent reasonably
practicable, the timing of the initial press releases in order to accomplish the same promptly upon execution and delivery of this Agreement.
The initial press releases of the Parties are attached hereto as Exhibit 12.5(a). Except to the extent already disclosed
in a press release or other public communication issued in accordance with this Agreement, no public announcement concerning this Agreement,
its subject matter or the transactions described herein shall be made, either directly or indirectly, by either Party or its Affiliates,
except as may be required, in the good faith discretion of such Party’s counsel, by Applicable Law (including disclosure requirements
of the U.S. Securities and Exchange Commission (“SEC”)), judicial order, or stock exchange or quotation system rule
without first obtaining the approval of the other Party and agreement upon the nature, text and timing of such announcement, which approval
and agreement shall not be unreasonably withheld or delayed. The Party desiring to make any such voluntary public announcement shall
provide the other Party with a written copy of the proposed announcement in reasonably sufficient time prior to public release to allow
the other Party to comment upon such announcement, prior to public release. In the case of press releases or other public communications
required to be made by law, judicial order or stock exchange or quotation system rule, the Party making such press release or public
announcement shall provide to the other Party a copy of the proposed press release or public announcement in written or electronic form
upon such advance notice as is practicable under the circumstances for the purpose of allowing the notified Party to review and comment
upon such press release or public announcement. Under such circumstances, the releasing Party shall not be obligated to delay making
any such press release or public communication beyond the time when the same is required to be made. Neither Party shall be required
to seek the permission of the other Party to repeat any information regarding the terms of this Agreement or any amendment hereto that
has already been publicly disclosed by such Party or by the other Party in accordance with this Section 12.5(a); provided that
such information remains accurate as of such time and provided the frequency and form of such disclosure are reasonable.

 

(b) Each
Party may make public statements regarding this Agreement in response to questions by the press, analysts, investors or those attending
industry conferences or financial analyst calls, provided that any such public statement or press release: (i) is not inconsistent
with prior public disclosures or public statements made in accordance with Section 12.5(a) or as permitted by Section 12.3;
and (ii) does not reveal (A) information regarding the terms of this Agreement that have not previously been disclosed in accordance
with Section 12.5(a) or as permitted by Section 12.3 or (B) non-public information about the other Party.

 

(c) The
Parties shall reasonably coordinate in advance with each other in connection with the filing of this Agreement (including redaction of
certain provisions of this Agreement) with the SEC or other governmental agency or any stock exchange on which securities issued by a
Party or its Affiliate are traded. Each Party shall use reasonable efforts to seek and obtain confidential treatment for the provisions
of this Agreement that the Parties mutually agree to redact from such filing; provided that each Party shall ultimately retain ultimate
discretion to disclose such information to the SEC or any stock exchange or other governmental agency (as the case may be) as such Party
determines, based on advice of legal counsel, is required to be so disclosed. Except as expressly set forth in this Article 12, neither
Party (or its Affiliates) shall be obligated to consult with or obtain approval from the other Party with respect to any filings with
the SEC or any stock exchange or other governmental agency where such filings do not disclose Confidential Information of the other Party.

 

    42

     

    

 

 

12.6 Publications.
Each Party recognizes that the publication of scientific and medical papers regarding results of and other information regarding Products,
including oral presentations and abstracts, may be beneficial to both Parties provided such publications are subject to reasonable controls
to protect Confidential Information. Accordingly, a Party may review and comment on any material proposed for disclosure or publication
by the other Party, such as by oral presentation, manuscript or abstract, relating to the Development, Manufacture or Commercialization
Products or that includes Confidential Information of the other Party. Before any such material is submitted for publication or disclosure
(other than oral presentation materials and abstracts, which are addressed below), the Party proposing publication shall deliver a complete
copy to the other Party at least forty-five (45) days prior to submitting the material to a publisher or initiating such other disclosure,
and such other Party shall review any such material and give its comments to the Party proposing publication within thirty (30) days
of the delivery of such material to such other Party. With respect to oral presentation materials and abstracts, the Party proposing
publication shall deliver a complete copy to the other Party at least fourteen (14) days prior to the anticipated date of the presentation,
and such other Party shall make reasonable efforts to expedite review of such materials and abstracts, and shall return such items as
soon as practicable to the Party proposing publication with appropriate comments, if any, but in no event later than ten (10) days from
the date of delivery to the non-publishing Party. The publishing Party shall comply with the other Party’s request to delete references
to the other Party’s Confidential Information in any such material and shall delay any submission for publication or other public
disclosure for a period of up to an additional sixty (60) days for the purpose of preparing and filing appropriate patent applications.
For clarity, this Section 12.6 is intended to set forth the procedures for scientific and medical presentations and publications, and
other public disclosures (e.g., press releases, investor presentations and the like) are addressed in Section 12.3 and Section 12.5.

 

Article
13

TERM AND TERMINATION

 

13.1 Term.
This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article 13, shall remain
in effect on Product-by-Product and a country-by-country basis, until the expiration of the Royalty Term of such Product in such country
(the “Term”). Upon the expiration of the Royalty Term for a Product in a particular country, the licenses granted
by Allarity to Oncoheroes under Section 2.1(a) with respect to such Product and such country shall become fully-paid, royalty free and
non-exclusive.

 

13.2 Unilateral
Termination by Oncoheroes. At any time after the first (1st) anniversary of the Effective Date, Oncoheroes may terminate
this Agreement in its entirety, for any or no reason upon (i) ninety (90) days’ written notice to Allarity if such notice is provided
prior to First Commercial Sale, and (ii) one hundred eighty (180) days’ written notice to Allarity if such notice is provided
on or after First Commercial Sale.

 

    43

     

    

 

13.3 Termination
by Either Party for Breach.

 

(a) Breach.
Subject to Section 13.3(b), each Party may terminate this Agreement upon written notice to the other Party if such other Party materially
breaches its obligations under this Agreement and, after receiving written notice from the non-breaching Party identifying such material
breach in reasonable detail, fails to cure such material breach within sixty (60) days from the date of such notice; provided that if
such breach is not reasonably capable of cure within such sixty (60)-day period, the breaching Party may submit a reasonable cure plan
prior to the end of such sixty (60)-day period, in which case the other Party shall not have the right to terminate this Agreement for
an additional period of thirty (30) days so long as the breaching Party is using Commercially Reasonable Efforts to implement such cure
plan.

 

(b) Disputed
Breach. If the alleged breaching Party disputes in good faith the existence or materiality of a breach specified in a notice provided
by the other Party in accordance with Section 13.3(a), and such alleged breaching Party provides the other Party notice of such dispute
within such sixty (60)-day period, then the non-breaching Party shall not have the right to terminate this Agreement under Section 13.3(a)
unless and until a court, in accordance with Article 14, has determined that the alleged breaching Party has materially breached this
Agreement and that such Party fails to cure such breach within sixty (60) days following such arbitrators’ decision. During the
pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to
perform all of their respective obligations hereunder.

 

13.4 Termination
for Patent Challenge. Allarity may terminate this Agreement in its entirety upon sixty (60) days’ written notice if Oncoheroes
or its Affiliates or Sublicensees, individually or in association with any other Person, commences a legal action anywhere in the world
challenging the validity, enforceability or scope of any Licensed Patent that is included in the License at such time (“Patent
Challenge”); provided that a Patent Challenge does not include any counterclaim or defensive challenge made in any legal
action or other proceeding commenced or maintained by Oncoheroes, its Affiliates or its Sublicensees in response to any claim or action
brought in the first instance by, or on behalf of Allarity or its Affiliates. The commencement of a Patent Challenge by Oncoheroes shall
not be grounds for termination of this Agreement if (i) such Patent Challenge is withdrawn or (ii) Oncoheroes demands in writing that
such Sublicensee withdraw such Patent Challenge and terminates its sublicense of the License to such Sublicensee, in each case ((i) and
(ii)) within sixty (60) days of Oncoheroes becoming aware of such Patent Challenge.

 

13.5 Termination
by Either Party for Bankruptcy. Either Party may terminate this Agreement if, at any time, the other Party (a) files in any court
or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy or insolvency or for
reorganization or for an arrangement or for the appointment of a receiver or trustee of such other Party or of its assets, (b) proposes
a written agreement of composition or extension of its debts, (c) is served with an involuntary petition against it, filed in any insolvency
proceeding that is not dismissed within sixty (60) days after the filing thereof, (d) proposes or is a party to any dissolution or liquidation,
or (e) makes an assignment for the benefit of its creditors.

 

    44

     

    

 

13.6 Full
Force and Effect During Notice Period. This Agreement shall remain in full force and effect until the expiration of the applicable
termination notice period. For clarity, if any Development Milestone Event is achieved during the termination notice period, then the
corresponding milestone payment in respect of such Development Milestone Event is accrued and Oncoheroes shall remain responsible for
the payment of such milestone payment even if the due date of such milestone payment may come after the effective date of the termination.

 

13.7 Effect
of Termination.

 

(a) Upon
termination of this Agreement by Oncoheroes pursuant to Section 13.2, or by Allarity pursuant to Sections 13.3, 13.4 or 13.5, the following
shall apply:

 

(i) Reversion
of Rights. All rights and licenses granted to Oncoheroes under this Agreement shall terminate and revert to Allarity;

 

(ii) Regulatory
Approval. In the event that this Agreement is terminated by Oncoheroes pursuant to Section 13.2 or by Allarity pursuant to Section
13.3, then, if at the time of termination of this Agreement, Oncoheroes holds or has rights in or to any Regulatory Approvals for the
Product, Oncoheroes shall assign to Allarity or a Third Party designated by Allarity all such Regulatory Approvals for the Product, at
Oncoheroes’ cost and expense. In addition, upon Allarity’s written request, Licensee shall, at Oncoheroes’ sole cost
and expense, provide to Allarity copies of all tangible Development Data and Regulatory Filings Controlled by Oncoheroes in the Territory
necessary or useful for obtaining Regulatory Approval. Upon any such termination, Oncoheroes shall grant and does hereby grant to Allarity
a transferrable Right of Reference to all Regulatory Filings pertaining to the Product submitted by or on behalf of Oncoheroes anywhere
in the Territory solely for the purpose of seeking, obtaining, and maintaining Regulatory Approval of Product, including in interactions
with any Regulatory Authority in connection with Development or Regulatory Approval of Product. The Parties shall discuss and establish
appropriate arrangements with respect to safety data exchange.

 

(iii) Inventory.
In the event that this Agreement is terminated in its entirety, Allarity shall have the right, but not the obligation, to purchase any
and all of the inventory of Product held by Oncoheroes or its Affiliates as of the date of termination, at a price equal to the Cost
of Goods of such inventory, together with any applicable external costs of transportation, storage and insurance, and import and export
taxes and fees. If Allarity does not elect to purchase such inventory from Oncoheroes, Oncoheroes shall have the right to continue to
sell such inventory of Product in the Licensed Field in the Territory for six (6) months after the date of termination of this Agreement,
subject to Oncoheroes’ continued payment of royalties on Net Sales of Product during such period in accordance with Section 8.3.

 

    45

     

    

 

(iv) Intellectual
Property.

 

(A) Oncoheroes
IP. Oncoheroes shall, and shall cause its Affiliates and Sublicensees to, disclose to Allarity (1) any and all Information Controlled
by Oncoheroes, its Affiliates, or Sublicensees as of the effective date of termination of this Agreement that has been generated by or
on behalf of Oncoheroes, its Affiliates or Sublicensees with respect to Product, (2) any Oncoheroes Inventions, and (3) any Patents
Controlled by Oncoheroes or its Affiliates that Cover the Product in the Licensed Field in the Territory, in each case that are necessary
or reasonably useful to enable Allarity to Develop and Commercialize Product in the Licensed Field (collectively, the “Oncoheroes
IP”). After receipt of the Oncoheroes IP, Allarity may notify Oncoheroes that it wishes to obtain a license to the Oncoheroes
IP to Develop and Commercialize Product in the Licensed Field. The Parties shall negotiate the terms of such license in good faith for
a period not to exceed ninety (90) days. The terms of such license will include a mutually agreed upon payment on signing of the license,
and will include milestone payments to become due upon the achievement of the then-remaining development milestone events set forth in
Section 8.2, together with royalty payments; it being understood and agreed that no payments shall be required in the case of any termination
by Oncoheroes pursuant to Section 13.2 or termination by Allarity pursuant to Section 13.3. Any such Oncoheroes IP shall be subject to
the confidentiality obligations and exemptions from confidentiality obligations set forth in Article 12. If the Parties are unable to
agree on the terms and execute a definitive agreement with respect to the Oncoheroes IP during such ninety (90)-day negotiation period,
then they may have such terms determined by baseball arbitration pursuant to Section 14.4.

 

(B) Regulatory
Filings. With respect to Product to which Allarity obtains a license pursuant to Section 13.7(a)(iv)(A), Oncoheroes shall and does
hereby assign, and shall cause its Affiliates and Sublicensees to assign, to Allarity all of their right, title and interest in and to
all Regulatory Filings with respect to such Product in the Licensed Field, including any Regulatory Approvals and applications therefor.

 

(C) Trademarks.
If, as of the effective date of termination, Oncoheroes has Commercialized the Product to which Allarity obtains a license pursuant to
Section 13.7(a)(iv)(A), Oncoheroes shall and hereby does grant Allarity a non-exclusive, royalty-bearing license under the Product Marks
to Commercialize such Product on commercially reasonable terms to be negotiated by the parties as part of the negotiation set forth in
Section 13.7(a)(iv)(A) (and, for the avoidance of doubt, in case of inability to agree on such terms such matter shall be included in
the baseball arbitration pursuant to Section 14.4).

 

(b) Subject
to Section 13.7(a), Allarity will not have any rights with respect to any Information generated by Oncoheroes with respect to such terminated
Product, to any Oncoheroes Inventions, or to any Patents Controlled by Oncoheroes or its Affiliates, and Oncoheroes will have no further
obligations to Allarity with respect to any such terminated Product.

 

(c) Subject
to Section 13.7(a), upon expiration or termination of this Agreement for any reason, each Party, at the request of the other Party, shall
return, or at the election of the other Party, destroy, and thereafter provide the other Party written certification evidencing such
destruction, all data, files, records and other materials in its or its Affiliates’ or, with respect to Oncoheroes, Sublicensees,
possession or control containing or comprising such other Party’s Confidential Information.

 

13.8 Survival.
Termination or expiration of this Agreement shall not affect any rights or obligations of the Parties under this Agreement that have
accrued prior to the date of termination or expiration. Notwithstanding anything to the contrary, the following provisions shall survive
any expiration or termination of this Agreement: Sections 2.3, 8.6 through 8.9 (inclusive), 9.1, 10.6, 13.7, and 13.8, and Articles 1,
11, 12, 14, and 15.

 

    46

     

    

 

Article
14

DISPUTE RESOLUTION

 

14.1 Disputes.
Except as provided in Section 3.1(d) and Section 14.4, upon the written request of either Party to the other Party, either
Party may refer any claim, dispute, or controversy or claim arising out of or related to this Agreement (a “Dispute”)
to the Senior Executive of Oncoheroes and the Senior Executive of Allarity for resolution. If the Senior Executives are unable to resolve
such matter within thirty (30) days after the initial written request, then, upon the written demand of either Party, the Parties
shall resolve such matter pursuant to the dispute resolution, as provided in Section 14.2.

 

14.2 Dispute
Resolution. The federal courts of New York shall have the exclusive jurisdiction over the Parties with respect to any dispute or
controversy between them arising under or in connection with this Agreement, and by execution and delivery of this Agreement, the Parties
to this Agreement submit to the jurisdiction of those courts, including, but not limited to, the in personam and subject matter jurisdiction
of those courts, waive any objection to such jurisdiction on the grounds of venue or forum non conveniens, the absence of in personam
or subject matter jurisdiction and any similar grounds, consent to service of process by mail in accordance with Section 15.9 or any
other manner permitted by law and irrevocably agree to be bound by any such judgment rendered thereby in connection with this Agreement.

 

14.3 Injunctive
Relief; Court Actions. Either Party may apply to the courts for interim injunctive relief until a judgment is rendered or the controversy
is otherwise resolved.

 

14.4 Baseball
Arbitration. If the Parties fail to agree on any matter described in Section 2.2 or Section 6.4(a) and a Party submits such
failure to baseball arbitration for final resolution, then relevant failure to agree shall be resolved in accordance with this Section 14.4.
Within ten (10) Business Days following a Party’s receipt of any baseball arbitration notice from the other Party, the Parties
shall meet and attempt to agree on an independent Third Party expert with at least ten (10) years of experience in the licensing of biopharmaceutical
compounds or products. If the Parties cannot agree on such expert within such time period, then each Party may nominate one independent
expert within ten (10) Business Days after such ten (10)-Business Day period and the two experts so selected shall nominate the final
independent expert within ten (10) Business Days of their nomination. Within ten (10) Business Days of her or their appointment, the
expert(s) shall set a date for the arbitration, which date shall be scheduled as soon as possible and is intended to be scheduled no
more than sixty (60) days after the date the arbitration is demanded. At least fifteen (15) Business Days prior to the arbitration, each
Party shall provide the expert with a complete, written proposal of such Party’s solution to the applicable Dispute, along with
any documentary or other evidence it wishes to provide in support for such proposal. After receiving both Parties’ proposals, the
expert(s) will have the right to meet with the Parties as necessary to inform the expert’s determination and to perform independent
research and analysis. The expert(s) will be instructed to select one of the Party’s proposals without modification within thirty
(30) days following the receipt of both proposals. The expert(s) will deliver her/their decision regarding the disputed matter in writing,
which decision will be made in accordance with the standard for resolution of such matter set forth in this Agreement and will be binding
and conclusive upon both Parties. The Party whose proposal is not selected by the experts is responsible for the fees of the experts
and the costs and expenses of the baseball arbitration. The provisions of Section 14.3 apply to any baseball arbitration proceedings
commenced under this Section 14.4 mutatis mutandis.

 

    47

     

    

 

14.5 Patent
and Trademark Disputes. Any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any
patents or trademarks covering the Manufacture, use, importation, offer for sale or sale of a Product shall be submitted to a court of
competent jurisdiction in the country in which such patent or trademark rights were granted or arose.

 

Article
15

MISCELLANEOUS

 

15.1 Rights
Upon Bankruptcy. All rights and licenses granted under or pursuant to this Agreement to Oncoheroes or Allarity are, and shall otherwise
be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code and other similar foreign laws, licenses of
rights to “intellectual property” as defined under Section 101 of the United States Bankruptcy Code or other similar
foreign laws. The Parties shall retain and may fully exercise all of their rights and elections under the United States Bankruptcy Code
(or any comparable provision of the laws applicable to bankruptcies or insolvencies), and other similar foreign laws. The Parties further
agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the United States Bankruptcy Code,
or other similar foreign laws, the non-debtor Party shall be entitled to a complete duplicate of (or complete access to, as appropriate)
any such intellectual property and all embodiments of such intellectual property and the same, which, if not already in the non-debtor
Party’s possession, shall be promptly delivered to it (a) upon any such commencement of a bankruptcy proceeding upon the non-debtor
Party’s written request therefor, unless the debtor Party continues to perform all of its obligations under this Agreement or (b) if
not delivered under clause (a) above, following the rejection of this Agreement by or on behalf of the debtor Party upon written
request therefor by the non-debtor Party.

 

15.2 Governing
Law. This Agreement and any disputes, claims, or actions related thereto shall be governed by and construed in accordance with the
laws of the State of New York, without regard to any conflicts of law provisions thereof that might otherwise refer construction or interpretation
of this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the application to this Agreement of the
United Nations Convention on Contracts for the International Sale of Goods.

 

15.3 Entire
Agreement; Amendment. This Agreement, including the Exhibits hereto, is both a final expression of the Parties’ agreement and
a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior and contemporaneous agreements
and communications, whether oral, written or otherwise, concerning any and all matters contained herein. This Agreement may only be modified
or supplemented in a writing expressly stated for such purpose and signed by an authorized representative of each Party.

 

    48

     

    

 

15.4 Relationship
Between the Parties. The Parties’ relationship, as established by this Agreement, is solely that of independent contractors.
This Agreement does not create any partnership, joint venture or similar business relationship between the Parties. Neither Party is
a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty or guarantee,
express or implied, on behalf of the other Party for any purpose whatsoever. The Parties (and any successor, assignee, transferee, or
Affiliate of a Party) shall not treat or report the relationship between the Parties arising under this Agreement as a partnership for
United States tax purposes, without the prior written consent of the other Party unless required by Applicable Law.

 

15.5 Non-Waiver.
The failure of a Party to insist upon strict performance of any provision of this Agreement or to exercise any right arising out of this
Agreement shall neither impair that provision or right nor constitute a waiver of that provision or right, in whole or in part, in that
instance or in any other instance. Any waiver by a Party of a particular provision or right shall be in writing, shall be as to a particular
matter and, if applicable, for a particular period of time and shall be signed by an authorized representative of such Party.

 

15.6 Assignment.
Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred
by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld); provided,
however, that either Party may assign this Agreement and its rights and obligations hereunder without the other Party’s
consent (a) to an Affiliate of such Party, provided that the assigning Party shall remain liable and responsible to the non-assigning
Party hereto for the performance and observance of all such duties and obligations by such Affiliate, and (b) in connection with the
transfer or sale of all or substantially all of the assets of such Party to a Third Party, whether by merger, sale of stock, sale of
assets or otherwise, provided that in the event of a transaction (whether this Agreement is actually assigned or is assumed by the acquiring
Party by operation of law (e.g., in the context of a reverse triangular merger)). Any attempted assignment not in accordance with
this Section 15.6 shall be null and void and of no legal effect. The rights and obligations of the Parties under this Agreement are binding
upon and inure to the benefit of the successors and permitted assigns of the Parties, and the name of a Party appearing herein shall
be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent
of this section. Any assignment not in accordance with this Agreement is void.

 

15.7 No
Third-Party Beneficiaries. This Agreement is neither expressly nor impliedly made for the benefit of any Party other than those executing
it.

 

15.8 Severability.
If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable or illegal by a court of competent jurisdiction,
such adjudication shall not affect or impair, in whole or in part, the validity, enforceability or legality of any remaining portions
of this Agreement. All remaining portions shall remain in full force and effect as if the original Agreement had been executed without
the invalidated, unenforceable or illegal part.

 

15.9 Notices.
Any notice to be given under this Agreement must be in writing and delivered either in person, by any method of mail (postage prepaid)
requiring return receipt, or by overnight courier or electronic mail confirmed thereafter by any of the foregoing, to the Party to be
notified at its address(es) given below, or at any address such Party has previously designated by prior written notice to the other.
Notice shall be deemed sufficiently given for all purposes upon the earliest of: (a) the date of actual receipt; (b) if delivered
by overnight courier, the next Business Day the overnight courier regularly makes deliveries; or (c) if sent by electronic mail,
upon electronic confirmation of receipt.

 

    49

     

    

 

	If
    to Allarity:	Allarity
                                            Therapeutics A/S

    210
    Broadway #201

    Cambridge,
    MA 02139

    Attention:_James
    Cullem, Chief Business Officer

    Email:
    jcullem@allarity.com

     

	With
    a copy (which shall not constitute notice) to:	Orrick,
                                            Herrington & Sutcliffe LLP

    1152
    15th Street, N.W

    Washington,
    D.C. 20005-1706

    Attention:
    David E. SchulmanEmail: dschulman@orrick.com

     

	If
    to Oncoheroes:	Oncoheroes
                                            Biosciences Inc.

    62
    Cypress Street #5

    Brookline,
    MA 02445

    Attention:
    Ricardo Garcia, CEO

    Email:
    rgarcia@oncoheroes.com

     

	With
    a copy to:	Cooley
                                            LLP

    500
    Boylston Street

    14th
    Floor

    Boston,
    MA 02116-3736

    United
    States of America

    Attention:
    Geoffrey J. Spolyar

    Email:
gspolyar@cooley.com

 

15.10 Force
Majeure. Each Party shall be excused from the performance of their obligations under this Agreement to the extent that such performance
is prevented by force majeure and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse
shall be continued only for so long as (a) the condition constituting force majeure continues and (b) the nonperforming Party takes all
reasonable efforts to remove the condition. For purposes of this Agreement, force majeure includes conditions beyond the reasonable control
of the applicable Party, which may include an act of God, war, civil commotion, terrorist act, labor strike or lock-out, epidemic, pandemic,
quarantine, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake,
storm or like catastrophe, action or inaction of any Governmental Authority, and failure of plant or machinery. Notwithstanding the foregoing,
a Party shall not be excused from making payments owed hereunder because of a force majeure affecting such Party. If a force majeure
persists for more than ninety (90) days, then the Parties shall discuss in good faith the modification of the Parties’ obligations
under this Agreement in order to mitigate the delays caused by such force majeure.

 

    50

     

    

 

15.11 Interpretation.
The headings of clauses contained in this Agreement preceding the text of the sections, subsections and paragraphs hereof are inserted
solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation
or construction. All references in this Agreement to the singular shall include the plural where applicable. Unless otherwise specified,
references in this Agreement to any Article shall include all Sections, subsections and paragraphs in such Article, references to any
Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include
all paragraphs in such subsection. All references to days in this Agreement means calendar days, unless otherwise specified. Ambiguities
and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed
to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language and the English language
shall control its interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic,
oral or other communications between the Parties regarding this Agreement shall be in the English language.

 

15.12 Construction.
Except where the context expressly requires otherwise, (a) the use of any gender herein encompasses references to either or both
genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b) the words “include”,
“includes” and “including” are deemed followed by the phrase “without limitation”, (c) any definition
of or reference to any agreement, instrument or other document herein refers to such agreement, instrument or other document as from
time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications
set forth herein), (d) any reference herein to any person includes the person’s successors and assigns, (e) the words
“herein”, “hereof” and “hereunder”, and words of similar import, refer to this Agreement in its entirety
and not to any particular provision hereof, (f) all references herein to Sections or Exhibits refer to Sections or Exhibits of this
Agreement, and references to this Agreement include all Exhibits hereto, and (g) the word “or” is disjunctive but not
necessarily exclusive.

 

15.13 Performance
by Affiliates. Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each Party
hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement, and shall cause its Affiliates
to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of
such Party’s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly
against such Party without any obligation to first proceed against such Party’s Affiliate.

 

15.14 Counterparts.
This Agreement may be executed in counterparts, including by transmission of facsimile or PDF copies of signature pages to the Parties
or their representative legal counsel, each of which shall be deemed an original document, and all of which, together with this writing,
shall be deemed one instrument.

 

[Remainder
of this page intentionally left blank.]

 

    51

     

    

 

In
Witness Whereof, the Parties have executed this
Exclusive License Agreement by their duly authorized officers as of the Effective Date.

 

	Oncoheroes Biosciences Inc.	 	Allarity Therapeutics A/S
	 	 	 	 	 
	By:	              	 	By:	            
	Name:	 	 	Name:	 
	Title:	 	 	Title:	 

 

     

     

    

 

Annex
I

 

Compound

 

[***]

 

     

     

    

 

Exhibit
1.58: Pediatric Indications comprising the Licensed Field

 

Brain
Cancers: 

		●	Angiocentric
                                            glioma

		●	Astrocytoma

		●	Diffuse
                                            intrinsic pontine gliomas/ Diffuse midline gliomas (DIPG/DMG)

		●	Dysembryoplastic
                                            neuroepithelial tumor (DNET)

		●	Ganglioma

		●	Gliomatosis
                                            cerebri

		●	Gliosarcoma

		●	Oligodendroglioma

		●	Optic
                                            nerve glioma

		●	Pleomorphic
                                            xanthoastrocytoma (PXA)

		●	Pediatric
                                            Glioblastoma

		●	Medulloblastoma

		●	Neurocytoma

 

Other
Neural tumors, including:

		●	Atypical
                                            teratoid rhabdoid tumor (ATRT)

		●	Neuroblastoma

		●	Primitive
                                            neuroectodermal tumors (PNET) and pineoblastoma

		●	Retinoblastoma

		●	Paraganglioma

		●	Choroid
                                            plexus tumors

		●	Craniopharyngioma

		●	Ependymoma

		●	Ependymoblastoma

		●	Meningioma

		●	Neurofibroma/plexiform
                                            neurofibroma

		●	Schwannoma
                                            (neurilemoma)

		●	Spinal
                                            cord tumors

 

Sarcomas:

		●	Alveolar
                                            soft part sarcoma

		●	Angiosarcoma

		●	Atypical
                                            teratoid-rhabdoid tumors

		●	Chondrosarcoma

		●	Chordoma

		●	Clear
                                            cell sarcoma

		●	Desmoid-type
                                            fibromatosis

		●	Ewing’s
                                            sarcoma

		●	Fibroblastic
                                            sarcoma

		●	Leiomyosarcoma

		●	Liposarcoma

		●	Malignant
                                            peripheral nerve sheath tumor (MPNST)

 

     

     

    

 

		●	Osteosarcoma

		●	Retroperitoneal
                                            sarcoma

		●	Rhabdomyosarcoma

		●	Soft
                                            tissue sarcoma

		●	Synovial
                                            sarcoma

 

Hematological
cancers:

		●	Burkitt’s
                                            Lymphoma

		●	Pediatric
                                            Acute Lymphoblastic Leukemia

		●	Pediatric
                                            Acute Myeloid/Myelogenous Leukemia

		●	Pediatric
                                            Acute Megakaryocytic Leukemia

		●	Pediatric
                                            Acute Myeloblastic Leukemia

		●	Pediatric
                                            Acute Myelogenous Leukemia

		●	Pediatric
                                            Acute Myeloid Leukemia

		●	Pediatric
                                            Acute Myelomonocytic Leukemia

		●	Pediatric
                                            Acute Promyelocytic Leukemia

		●	Juvenile
                                            myelomonocytic leukemia

		●	Hodgkin’s
                                            disease/lynphoma

 

Others:

		●	Germ
                                            cell tumors

		●	Germinoma

		●	Pheochromocytoma

		●	Hepatoblastoma

		●	Nephroblastoma

		●	Wilms
                                            Tumor

		●	Li-Fraumeni
                                            syndrome

		●	Tuberous
                                            sclerosis

		●	Pituitary
                                            tumors

 

     

     

    

 

Exhibit
1.60: Licensed Patents

 

	Jurisdiction		Application No./ Patent No.
	 	Status
	United States	 	U.S. 7,335,774	 	Granted
	Australia	 	AU 2003226275	 	Granted
	Canada	 	CA 2,481,055	 	Granted
	Europe 
  Validation states: AT, BE, CH, DE, ES, FR, GB, IT, NL	 	EP 1497287	 	Granted
	United States	 	U.S. 9,545,402	 	Granted
	Australia	 	AU 2011273519	 	Granted
	Canada	 	CA 2,801,826	 	Granted
	China	 	CN 106943355	 	Granted
	Europe 
  Validation states: AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IT, NL, NO, PL, PT, SE, TR	 	EP 2588086	 	Granted
	Europe	 	EP 3446686	 	Pending
	India	 	10795/DELNP/2012	 	Pending
	Japan	 	JP 2013-517282	 	Granted
	U.S.	 	U.S. 8,741,903	 	Granted
	Australia	 	AU 201123999	 	Granted
	Europe

                                                        Validation states: AT, BE, CH, CZ, DE, DK, ES, FI, FR, GB, GR, HU, IE, IT, NL, NO, PL, PT, SE, TR
	 	EP 2558095	 	Granted

 

Platform
Patents (as defined in Novartis Head License Agreement) 

 

PCT/US2003/010463

 

Product-Specific
Patents (as defined in Novartis Head License Agreement)

 

PCT/US2001/042131

 

PCT/EP2011/055906

 

PCT/EP2011/060949

 

PCT/US2013/023781

 

PCT/US2003/010463

 

PCT/US2012/029205

 

     

     

    

 

Exhibit
1.62: Licensed Marks

 

N/A

 

     

     

    

 

Exhibit
1.91: Upstream Licenses

 

[***]

 

     

     

    

 

Exhibit
12.5(a): Press ReleaseExhibit 10.20

 

CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD
BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

Execution
Copy

 

Amended
and Restated License Agreement

 

Dated
as of 28 March 2022

 

     

     

    

 

LiPlasome
Pharma ApS

Business
registration no.: 29428514

Tabletvej
1

DK-7100
Vejle

(hereinafter
“LiPlasome” or “Licensor”)

 

and

 

Allarity
Therapeutics Europe ApS

(formerly
known as Medical Prognosis Institute A/S and Oncology Venture A/S)

Business
registration no.: 34623562

Venlighedsvej
1

DK-2970
Hørsholm

(hereinafter
“ALLARITY”)

 

and

 

Chosa
ApS

Business
registration no.: 43134477

Frederiksgade
17

DK-1265
København K

 

(hereinafter
“Chosa” or “Licensee”)

 

(hereinafter
referred to separately as a “Party” and collectively as the “Parties”)

 

have
today entered into this

 

AMENDED
AND RESTATED LICENSE AGREEMENT

(the “Agreement”)

 

regarding
Chosa’s development and commercialization of LiPlaCis as a cancer treatment drug.

 

		1.	Background

 

		1.1	Whereas
                                            LiPlasome and Allarity Therapeutics Europe ApS (formerly known as Oncology Venture Product
                                            Development ApS), business registration no. 34623562 (entered into a certain License
                                            Agreement for LiPlaCis, effective as of 15 February 2016 as amended as of January 27,
                                            2021 (the “Original Agreement”).

 

		1.2	Whereas
                                            LiPlasome owns and has developed a third-generation liposomal delivery technology and related
                                            intellectual property rights which has led to the creation of a range of products for the
                                            treatment of cancer, including a targeted, liposomal formulation of the chemotherapeutic
                                            Cisplatin (“LiPlaCis”).

 

    2

     

    

 

		1.3	Whereas,
                                            prior to the execution of the Original Agreement, LiPlasome invested considerable resources
                                            in the development of LiPlaCis as a cancer treatment drug including the conduct of a phase
                                            1 study at Rigshospitalet (Denmark) which was to be followed by a phase 1 extension study,
                                            as well as a phase 1 study in the Netherlands.

 

		1.4	Whereas,
                                            prior to the execution of the Original Agreement, the current and previous LiPlasome shareholders
                                            invested approximately DKK 62,500,000 in the LiPlasome Patents and studies and were seeking
                                            a partner to continue the ongoing and planned studies.

 

		1.5	Whereas,
                                            the Parties wish to assign, amend and restate the Original Agreement in order to (i) simplify
                                            the terms and conditions of their Agreement and (ii) permit Chosa to replace ALLARITY
                                            as licensee under this Agreement and to further advance clinical development and commercialization
                                            of LiPlaCis in accordance with the terms of this Agreement.

 

		1.6	Now
                                            therefore, the Parties have entered into this Agreement.

 

		2.	Definitions

 

		2.1	“Affiliate”
                                            means any entity that, directly or indirectly, through one or more intermediaries, Controls
                                            or is Controlled by, or is under common Control with a Party, except that in countries where
                                            ownership of a majority or Controlling interest by a foreign entity is not permitted by law,
                                            rule or regulations, the foreign entity’s direct or indirect voting interest may be
                                            less than a majority or Controlling interest.

 

		2.2	“Combination
                                            Product” means a Product that contains one or more additional active ingredients (whether
                                            co-formulated or co-packaged) that are neither the Product nor generic compositions of matter
                                            equivalents thereof.

 

		2.3	“Control”
                                            means the ability, directly or indirectly, to direct the affairs of another by means of:
                                            (i) ownership of at least fifty per cent (50%) of the voting shares in any entity,
                                            or, in the case of an entity that has no outstanding securities, having the right to fifty
                                            per cent (50%) or more of the profits of the entity, or having the right in the event
                                            of dissolution to fifty per cent (50%) or more of the assets of the entity; or (ii) by
                                            contract or otherwise.

 

		2.4	“DRP®
                                            Companion Diagnostics” means the DRP® biomarkers and algorithms developed by ALLARITY
                                            that specifically predict likelihood of patient response to LiPlaCis and/or Cisplatin, as
                                            more specifically covered by and described in US Patent No. 10,907,214; EP 3342879; HK 1255416;
                                            PCT/EP2008/003789; US Patent No. 8,445,198; CA 2,631,236; CN ZL200680052220.2; and JP 5984324;
                                            PCT/IB2011/001405; US Patent No. 9,598,734; AU 2011246976; and EP 2563936; and pending patent
                                            applications in the foregoing patent families; it being understood that the DRP®
                                            Companion Diagnostics shall include the DRP® biomarkers and algorithms that were used
                                            in the published lung cancer study by Ida Kappel Buhl Plos One https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194609
                                            as well as for the LiPlaCis Phase 2 study.

 

    3

     

    

 

		2.5	“DRP®
                                            Companion Diagnostics License” has the meaning given to it in clause 3.5.

 

		2.6	“Effective
                                            Date” has the meaning given to it in clause 9.1.

 

		2.7	“EMA”
                                            means the European Medicines Agency or the equivalent Regulatory Authority with competent
                                            jurisdiction in the United Kingdom or any successor entity to either of the foregoing.

 

		2.8	“Europe”
                                            means European Union as of the Effective Date, together with the United Kingdom.

 

		2.9	“European
                                            Union” or “EU” means the European Union member states as then constituted.
                                            As of the Effective Date, the European Union member states are Austria, Belgium, Bulgaria,
                                            Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary,
                                            Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania,
                                            Slovakia, Slovenia, Spain, and Sweden.

 

		2.10	“FDA”
                                            means the United States Food and Drug Administration, or any successor agency thereto in
                                            the United States.

 

		2.11	“Field”
                                            means the analysis and treatment of all cancers in human beings and animals.

 

		2.12	“Governmental
                                            Authority” means in any country the government entity having authority over the manufacturing,
                                            marketing, selling, pricing, reimbursement, testing, investigating or regulating of the Product,
                                            and all states or other political subdivisions thereof and supranational bodies applicable
                                            thereto, including Europe, and all agencies, commissions, officials, courts or other instrumentalities
                                            of the foregoing.

 

		2.13	“IFRS”
                                            means the International Financial Reporting Standards developed by the International Accounting
                                            Standards Board from time to time, consistently applied.

 

		2.14	"Licenses”
                                            means the LiPlasome License and the DRP® Companion Diagnostic License collectively.

 

		2.15	The
                                            “LiPlasome License” has the meaning given to it in clause 3.2.

 

		2.16	"LiPlaCis"
                                            has the meaning given to it in clause 1.2.

 

		2.17	“LiPlasome
                                            Patents” has the meaning given to it in clause 3.1.

 

    4

     

    

 

		2.18	“LiPlaCis
                                            Support Agreement” means the LiPlaCis Support Agreement dated as of the Effective Date
                                            to which Allarity Therapeutics Europe ApS, Allarity Therapeutics A/S, Smerud Medical Research
                                            International AS, Chosa ApS and LiPlasome Pharma ApS are parties and to which this Agreement
                                            is attached as Exhibit A.

 

		2.19	“LiPlasome
                                            Trademarks” has the meaning given to it in clause 3.1.

 

		2.20	“New
                                            IPR” has the meaning given to it in clause 7.7.

 

		2.21	“Net
                                            Sales” means, on a country-by-country and Product-by-Product basis in the Territory,
                                            with respect to any period for each country, the gross amounts invoiced by Chosa or its respective
                                            Affiliates or its or their respective sublicensees or assignees (each, a “Selling Party”),
                                            as applicable, to Third Parties (who are not sublicensees or assignees) for sales of a Product
                                            in the Field in such country, less the following deductions to the extent included in the
                                            gross invoiced sales price for such Product or otherwise directly paid, incurred, allowed,
                                            accrued or specifically allocated by the Selling Parties with respect to the sale of such
                                            Product in such country: (a) discounts, including trade, quantity or cash discounts, credits,
                                            adjustments or allowances, including those granted on account of price adjustments, billing
                                            errors, rejected goods, or damaged goods, which discounts are applied on a basis consistent
                                            with the selling Person’s practices with respect to the selling Person’s other
                                            pharmaceutical products; (b) rebates and chargebacks allowed, given or accrued (including
                                            cash, governmental and managed care rebates, hospital or other buying group chargebacks,
                                            cash and non-cash coupons, retroactive price reductions, and governmental taxes in the nature
                                            of a rebate based on usage levels or sales of such Product); (c) sales, excise, turnover,
                                            inventory, value-added, import, export, excise (including annual fees due under Section 9008
                                            of the United States Patient Protection and Affordable Care Act of 2010 (Pub. L. No. 111-48)
                                            and other comparable laws) and other taxes levied on, absorbed, determined or imposed with
                                            respect to the sale of such Product (excluding income or net profit taxes or franchise taxes
                                            of any kind); (d) freight and insurance charges, customs charges, postage, shipping, handling,
                                            REMS compliance costs and other transportation costs incurred in shipping such Product; (e)
                                            amounts paid or credited to customers for bona fide inventory management services; and (f)
                                            the portion of any management fees paid during the relevant time period to group purchasing
                                            organizations, wholesalers and managed care organizations to the extent determined by sales
                                            or utilization of such Product. Net Sales will be determined in accordance with IFRS. Without
                                            limiting the generality of the foregoing, transfers or dispositions of a Product for charitable,
                                            promotional (including samples), pre-clinical, clinical, or regulatory purposes where no
                                            consideration is exchanged will be excluded from Net Sales, as will sales or transfers of
                                            a Product among the Selling Parties.

 

Subject
to the above deductions, Net Sales shall be deemed to occur on, and only on, the first sale by a Selling Party to a non-sublicensee and
non-assignee Third Party. If non-monetary consideration is received by a Selling Party for the Product in the relevant country, Net Sales
will be calculated based on the average price charged for such Product, as applicable, during the preceding period, or in the absence
of such sales, the fair market value of the Product, as applicable, as determined by the Parties in good faith.

 

    5

     

    

 

If
a Product is sold as part of a Combination Product, Net Sales will be the product of (i) Net Sales of the Combination Product calculated
as above (i.e., calculated as for a non-Combination Product) and (ii) the fraction (A/(A+B)), where:

 

“A”
is the gross invoice price in such country of the applicable Product as the sole therapeutically active ingredient; and

 

“B”
is the gross invoice price in such country of the other therapeutically active ingredients contained in the Combination Product.

 

If
“A” or “B” cannot be determined by reference to non-Combination Product sales as described above, then Net Sales
will be calculated as above, but the gross invoice price in the above equation shall be determined by mutual agreement reached in good
faith by the Parties prior to the end of the accounting period in question based on an equitable method of determining the same that
takes into account, in the applicable country, variation in dosage units and the relative fair market value of each therapeutically active
ingredient in the Combination Product.

 

		2.22	The
                                            “Original Agreement” has the meaning given to it in clause 1.1.

 

		2.23	“Person”
                                            means any individual or entity (including partnerships, corporations, limited liability companies,
                                            trusts and governmental authorities).

 

		2.24	“Product”
                                            means all preparations, compositions and formulations of LiPlaCis or any other formulations
                                            of cisplatin, together with all current and future formulations, versions, compositions and
                                            presentations of product, together with any improvements or modifications, that use either
                                            LiPlaCis or any other formulations of cisplatin as its active pharmaceutical ingredient alone
                                            or in combination with other therapeutically or prophylactically active pharmaceutical ingredients
                                            as part of a Combination Product.

 

		2.25	“Proprietary
                                            Rights” has the meaning given to it in clause 7.1.

 

		2.26	Prosecution”
                                            means, with respect to LiPlasome Patents, the preparation of, filing for, prosecuting, responding
                                            to oppositions, nullity actions, re-examinations, revocation actions and similar proceedings
                                            (including conducting or participating in interference, oppositions, reissue proceedings,
                                            reexaminations, post-grant proceedings and any other similar proceeding relating thereto)
                                            filed by Third Parties against, and maintaining, LiPlasome Patents.

 

		2.27	“Regulatory
                                            Approval” means, with respect to a pharmaceutical product in a particular jurisdiction,
                                            all approvals or other permissions from the applicable Regulatory Authority in such jurisdiction
                                            necessary to market and sell such product in such jurisdiction, including pricing and reimbursement
                                            approvals if required prior to the first marketing or sale of such product in such jurisdiction.

 

    6

     

    

 

		2.28	“Regulatory
                                            Authority” means any applicable Governmental Authority having the administrative authority
                                            to regulate the manufacturing, development, commercialization, reimbursement or pricing,
                                            as applicable, for the Product, including Regulatory Approvals, including the FDA and the
                                            EMA or by any applicable Governmental Authority in any member state of the European Union
                                            or in the United Kingdom.

 

		2.29	“Smerud”
                                            means Smerud Medical Research International AS, Thunes Vei 2, N-0274 Oslo, Norway.

 

		2.30	“Territory”
                                            means worldwide.

 

		2.31	“Third
                                            Party” means any Person other than the Parties and their Affiliates.

 

		2.32	Clause
                                            headings herein are for ease of reference only and shall not affect the interpretation of
                                            this Agreement. Annexes form part of this Agreement and have effect as if set out in the
                                            body of this Agreement. Reference to this Agreement includes reference to the Annexes. In
                                            the event of inconsistency between the body of this Agreement and an Annex, the body of this
                                            Agreement shall prevail.

 

		2.33	Reference
                                            to (a) days means calendar days; (b) persons includes a natural person, corporate
                                            or unincorporated body (whether or not having separate legal personality); (c) one gender
                                            includes other genders; (d) a Party includes that Party’s personal representatives,
                                            successors or permitted assigns; (e) a statute, statutory provision or subordinated
                                            legislation includes such items as amended or re- enacted from time to time, whether before
                                            or after the date of this Agreement; (f) writing or written includes e-mail; (g) a
                                            document includes varied or novated documents; and (h) including, include, in particular
                                            or similar expressions are illustrative and do not limit the preceding words. Words in the
                                            singular include the plural and vice versa.

 

		3.	License

 

		3.1	LiPlaCis
                                            License. LiPlasome owns the LiPlaCis technology, including, but not limited to, the patent
                                            applications and patents listed in Exhibit B (collectively the “LiPlasome Patents”)
                                            and the trademarks listed in Exhibit C (collectively the “LiPlasome Trademarks”).

 

		3.2	Subject
                                            to the terms and conditions laid down in this Agreement, Chosa is hereby granted by Liplasome
                                            a global, perpetual, and exclusive license to use the LiPlaCis technology, including, but
                                            not limited to, the LiPlasome Patents and the LiPlasome Trademarks, any and all information
                                            and data, related to LiPlaCis generated, owned or controlled by LiPlasome, screening data
                                            related to LiPlaCis generated, owned or controlled by LiPlasome until and including 15 February
                                            2016 (including screening data from the Phase 1/2 clinical trial of LiPlaCis) conducted by
                                            LiPlasome, as well as screening data related to LiPlaCis generated by ALLARITY and Smerud
                                            after 15 February 2016 and owned by LiPlasome in accordance with clause 7.6 of the Original
                                            Agreement (the “LiPlasome License”). The LiPlasome License grants Chosa all rights
                                            to research, develop, manufacture, use, import, export, distribute, promote, market, offer
                                            for sale, sell, sub-license (through multiple tiers) and otherwise exploit and commercialize
                                            LiPlaCis for any indication or use without limitation worldwide.

 

    7

     

    

 

		3.3	For
                                            the avoidance of doubt, except for the screening data, cf. clause 7.11, the LiPlasome
                                            License covers LiPlaCis only. LiPlasome shall be entitled and obligated to retain, maintain,
                                            obtain and hold all LiPlasome Patents, LiPlasome Trademarks and the screening data referred
                                            to in clause 3.2, and shall have the sole right under the LiPlasome Patents and LiPlasome
                                            Trademarks to develop, manufacture, have made, use, import, export, distribute, promote,
                                            market, offer for sale, sell, sub-license and otherwise exploit and commercialize all other
                                            products than LiPlaCis worldwide.

 

		3.4	For
                                            the avoidance of doubt, this Agreement shall be deemed to amend and replace the Original
                                            Agreement.

 

		3.5	DRP®
                                            Companion Diagnostics License. Subject to the terms and conditions of this Agreement, ALLARITY
                                            (i) hereby grants Chosa an exclusive, perpetual, fully paid-up, royalty-free, transferable,
                                            sublicensable (through multiple tiers) license to the DRP® Companion Diagnostics, including
                                            Exhibit A, solely for research, development and commercialization of Products in the Territory
                                            in the Field and (ii) hereby grants Chosa a non-exclusive, perpetual, fully paid-up, royalty-free,
                                            transferable, sublicensable (through multiple tiers) license to use any and all know-how
                                            and intellectual property rights owned or controlled by ALLARITY relevant for Chosa's use
                                            of the DRP® Companion Diagnostics as contemplated in this Agreement solely for use in
                                            the development and commercialization of the Products in the Territory in the Field, including,
                                            but not limited to, any patents owned or controlled by ALLARITY for any use in the Territory
                                            in the Field (the “DRP® Companion Diagnostics License”); and (iii) hereby
                                            offers to Chosa (x) DRP® Companion Diagnostics testing support to Chosa in the European
                                            Union, Switzerland, Norway, Iceland and United Kingdom, at an agreed-upon cost per test not
                                            to exceed USD$[***], through the first Regulatory Approval of the Product in the Territory,
                                            all subject to a separate DRP® Companion Diagnostic services agreement to be entered
                                            into by the Parties on mutually agreed terms; and (y) assistance to Chosa in arranging DRP®
                                            Companion Diagnostics testing through ALLARITY’s existing CLIA laboratory partner Almac
                                            at a cost per test (to be paid by Chosa) set by Almac from time to time. For clarity, the
                                            DRP® Companion Diagnostics License shall include full access to and control of the algorithms,
                                            processes, and procedures relating to ALLARITY’s DRP® Companion Diagnostics. ALLARITY
                                            represents and warrants that the DRP® Companion Diagnostics will be the same as that
                                            used in the LiPlaCis Phase 2 study and, in connection with Chosa’s review and diligence
                                            of the DRP® Companion Diagnostics, ALLARITY provided Chosa the opportunity to review
                                            the operability of the DRP® Companion Diagnostics to Chosa at ALLARITY’s offices
                                            at Hoersholm, Denmark on March 21, 2022. No other right or license (implied or otherwise)
                                            is granted under this Agreement except as expressly set forth herein.

 

    8

     

    

 

		3.6	For
                                            a period of sixty (60) days from the Effective Date, ALLARITY shall use commercially
                                            reasonable efforts to provide reasonable assistance requested by Chosa to facilitate
                                            the transfer of  technical data and processes related to LiPlaCis and DRP®
                                            Companion Diagnostics to Chosa, and to transfer to Chosa the screening data licensed to Chosa
                                            under the LiPlasome License, by providing Chosa with reasonable access by teleconference
                                            or in-person to ALLARITY personnel involved in the research, development and manufacture
                                            of LiPlaCis, including through semi-monthly project transition calls with Chosa to address
                                            transition and outstanding issues; provided such ALLARITY personnel remain employed by ALLARITY
                                            or its Affiliates during such sixty (60) day period following the Effective Date.  From
                                            the Effective Date until the first regulatory filing by Chosa, ALLARITY will provide regulatory
                                            expertise and support to Chosa not to exceed one hundred (100) man-hours in the aggregate
                                            from all employees of ALLARITY or its Affiliates that are made available to Chosa at an FTE
                                            commercial market rate set by ALLARITY and agreed to by Chosa. All support provided by ALLARITY
                                            employees shall be coordinated and approved by ALLARITY, and Chosa shall not have direct
                                            access to ALLARITY employees outside of such coordination and approval by ALLARITY unless
                                            otherwise approved in writing by ALLARITY.

 

		3.7	For
                                            a period of sixty (60) days from the Effective Date, ALLARITY shall provide to Chosa access
                                            to allow Chosa to make copies of all of the materials provided in the data room set up by
                                            ALLARITY for this transaction, including, but not limited to, the information described in
                                            Exhibit A (including allowing Chosa to prepare a DVD ROM disc (or similar media) containing
                                            a digital copy) of all of the materials included in such data room, and ALLARITY shall for
                                            a period of thirty (30) days following the Effective Date provide Chosa access to any and
                                            all underlying source data and documents necessary for exploitation and use of available
                                            documents in the data room. As of the Effective Date, ALLARITY covenants that materials referred
                                            to in Exhibit A are included in the data room described in this Clause 3.7.

 

		4.	Chosa
                                            obligations

 

		4.1	Chosa
                                            warrants that it will timely and diligently fulfil all its obligations hereunder with the
                                            aim of maximising the commercialization of LiPlaCis and Products.

 

		4.2	Chosa
                                            will exercise commercially reasonable efforts to prepare a novel comprehensive information
                                            memorandum pitch package concerning LiPlaCis to be presented to potential external Third
                                            Parties, including the elaboration of Phase 2 clinical study reports and the U.S. FDA
                                            feedback received on (i) ALLARITY’s approved Investigation Device Exemption (IDE)
                                            to use the DRP for further U.S. clinical studies of LiPlaCis; and (ii) the IND filed
                                            to conduct a Phase 3/pivotal trial of LiPlaCis using the DRP to select and treat patients.

 

    9

     

    

 

		4.3	As
                                            of the Effective Date, Chosa shall take over and be responsible for the maintenance and enforcement
                                            of the LiPlasome Patents and the LiPlasome Trademarks, including pursuing pending patent
                                            applications, in the name of LiPlasome, and bear any and all external costs arising out thereof.
                                            In accordance with past practice LiPlasome will pay the ordinary maintenance costs of the
                                            LiPlasome Patents and the LiPlasome Trademarks subject to prompt reimbursement by Chosa.
                                            Specifications of the patent maintenance costs due in May and June 2022 have been submitted
                                            to Chosa by LiPlasome.

 

		4.4	Subject
                                            to clause 11 (confidentiality);

 

		(i)	Chosa
                                            will provide full transparency to update LiPlasome concerning its efforts to obtain Regulatory
                                            Approval or Net Sales of the Product and will, by the end of each calendar quarter, deliver
                                            a written report with supporting documentation and particulars concerning the current status;
                                            and

 

		(ii)	by
                                            the end of each year, Chosa will disclose to LiPlasome any material correspondence and documentation
                                            between Chosa and any actual or potential business partner to the extent related to the LiPlasome
                                            License.

 

		5.	Financial
                                            Terms

 

		5.1	As
                                            of the execution of this Agreement: (a) Smerud agreed to cancel Norwegian Kronor (NOK) [***]
                                            by way of debt cancellation relating to prior work by Smerud; and (b) ALLARITY agrees to
                                            pay to LiPlasome [***] per cent ([***]%) of such debt cancellation amount, equal to
                                            Norwegian Kronor (NOK) [***] (which may be payable in Danish Kroner as provided in the LiPlaCis
                                            Support Agreement), in immediately available funds on the Effective Date of this Agreement
                                            as provided in the LiPlaCis Support Agreement.

 

		5.2	Chosa
                                            shall make the following development milestone payments to ALLARITY and LiPlasome, with each
                                            of ALLARITY and LiPlasome receiving [***] percent ([***]%) of such amount at the time of
                                            each payment, that are set forth below upon the first achievement by or on behalf of Chosa
                                            or any other Selling Party of the applicable milestone events (“Milestone Events”)
                                            set forth below with respect to each Product, it being understood and agreed that in no event
                                            will more than one (1) milestone payment be paid with respect to any specific event triggering
                                            a payment under this Agreement.

 

	LiPlaCis

                                                

	Development
    Milestone Event	 	 	Milestone
                                            Payments
 (in USD)	 
	Receipt of first Regulatory
    Approval for the first Product in the United States	 	 	$[***]	 
	Receipt of first Regulatory
    Approval for the first Product in any country in Europe, including on a centralized filing basis by the EMA	 	 	$[***]	 
	First achievement (on a cumulative
    basis) of $[***] of Net Sales of Product by the Selling Parties in the United States	 	 	$[***]	 
	First achievement (on a cumulative
    basis) of $[***] of Net Sales of Product by the Selling Parties in any country in Europe	 	 	$[***]	 

 

    10

     

    

 

		5.3	Chosa
                                            shall transfer any relevant part of the Milestone Payments due under clause 5.2 to ALLARITY
                                            and LiPlasome, as applicable, no later than ten (10) days after Chosa has, or Chosa’s
                                            Affiliates, subsidiaries or shareholders have, achieved a Milestone Event together with statements
                                            of proceeds which shall include all relevant written information in order for ALLARITY and
                                            LiPlasome to establish the accuracy of the payments.

 

		5.4	No
                                            other payments of any kind are due by Chosa to ALLARITY or LiPlasome under this Agreement,
                                            other than specified in clauses 5.1 through 5.3 and/or as otherwise provided by this
                                            Agreement.

 

		6.	Audit
                                            and objection

 

		6.1	Upon
                                            reasonable written notice by ALLARITY or LiPlasome, Chosa shall permit ALLARITY or LiPlasome
                                            and ALLARITY’s or LiPlasome’s representative(s), as applicable, access to any
                                            area of Chosa’s facilities and books and records relating to the performance of this
                                            Agreement. Chosa shall ensure that a similar right can be exercised by ALLARITY or LiPlasome
                                            against Chosa’s subcontractors, sublicensees and other business partners. Such access
                                            shall include the right for LiPlasome and/or its representatives to conduct an audit to determine
                                            and ensure Chosa’s compliance with the terms and conditions of this Agreement, as well
                                            as a verification of the status of any Regulatory Approval by the U.S. FDA and any other
                                            Regulatory Authority, and the status and results of any clinical tests and trials.

 

		6.2	If
                                            ALLARITY or LiPlasome do not agree to the calculation of the amount of any Milestone Payments
                                            paid or payable in accordance with clause 5.2, ALLARITY or LiPlasome shall provide Chosa
                                            with a reasoned objection within four (4) weeks from receipt of the applicable Milestone
                                            Payment. If no such objection is filed in time, ALLARITY or LiPlasome shall be deemed to
                                            have agreed to the calculation. If ALLARITY or LiPlasome files an objection in time, the
                                            Parties shall negotiate to reach an agreement. In the event that the Parties have not reached
                                            an agreement within four (4) weeks following ALLARITY’s or LiPlasome’s objection,
                                            the Milestone Payments shall be determined as promptly as practicable by an independent auditor
                                            appointed, at the request of either Party, by FSR - Danske Revisorer. The independent auditor
                                            shall act as an expert only and is not competent to make decisions concerning the legal interpretation
                                            of the Agreement. Chosa shall provide the independent auditor unrestricted access to all
                                            books, records, information and documentation of Chosa and its subcontractors that the independent
                                            auditor in his discretion may consider relevant, as well as an opportunity to interview and
                                            ask written questions to employees, directors, consultants and subcontractors of Chosa. The
                                            independent auditor’s calculation of such Milestone Payments shall be final and binding
                                            upon the Parties, except in the event of manifest error. The independent auditor shall decide
                                            on the apportionment of cost and expenses of the independent auditor between the Parties
                                            and for this purpose, the independent auditor may take into consideration the degree to which
                                            the independent auditor’s calculation is in favour of the Parties’ respective
                                            positions.

 

		6.3	If
                                            the independent auditor identifies any underpayment of Milestone Payments to ALLARITY or
                                            LiPlasome, Chosa shall promptly pay to ALLARITY or LiPlasome, as applicable, the deficit
                                            with interest at a rate of six (6) months’ CIBOR (Copenhagen Inter Bank Offer
                                            Rate) plus five per cent (5%), with a floor of four per cent (4%). ALLARITY and LiPlasome
                                            each shall solely bear the costs of any audit initiated by ALLARITY or LiPlasome, as applicable,
                                            unless the independent auditor identifies an underpayment to ALLARITY or LiPlasome; in which
                                            case Chosa shall solely bear the costs of such audit.

 

    11

     

    

 

		7.	Intellectual
                                            property rights

 

Proprietary
rights

 

		7.1	All
                                            right, title and interest to the LiPlasome Patents (including applications, provisional applications,
                                            divisionals, continuations, continuations-in-part, reissues, and re-examinations) as well
                                            as the LiPlasome Trademarks, the screening data generated before or after 15 February
                                            2016 relating to LiPlaCis and any know-how, including any material containing or evidencing
                                            LiPlasome know-how disclosed by LiPlasome to Chosa shall belong solely and exclusively to
                                            LiPlasome (“Proprietary Rights”).

 

		7.2	Each
                                            of LiPlasome and Chosa shall promptly notify the other in writing in the event that it becomes
                                            aware of any third-party alleged infringement or challenge of the Proprietary Rights or the
                                            products covered by the LiPlasome License.

 

		7.3	Each
                                            of ALLARITY and Chosa shall promptly notify the other in writing in the event that it becomes
                                            aware of any third-party alleged infringement or challenge of the DRP® Companion Diagnostics
                                            covered by the DRP® Companion Diagnostics License.

 

		7.4	If
                                            any Proprietary Rights under the LiPlasome License are infringed or misappropriated by a
                                            Third Party or otherwise become the subject of legal or administrative proceedings, LiPlasome
                                            and Chosa shall jointly decide whether to pursue such infringement and all costs shall be
                                            split equally. In case LiPlasome and Chosa cannot agree whether to pursue infringements,
                                            either of LiPlasome and Chosa shall be entitled to initiate proceedings/negotiations on its
                                            own, however, in such case the costs related to such proceedings/negotiations shall be borne
                                            by either of LiPlasome and Chosa, as applicable, alone and all damages, fees, compensation,
                                            etc. and/or settlement amounts awarded or obtained during such proceedings/negotiations shall
                                            accrue to such Party as well. The foregoing shall also apply with respect to defending such
                                            Proprietary Rights in case of third-party claims of infringement by either LiPlasome and/or
                                            Chosa.

 

		7.5	Chosa
                                            will coordinate in good faith the enforcement, defense and Prosecution of the LiPlasome Patents,
                                            as well as any patent term extensions, adjustments, restorations or supplementary protection
                                            certificates with respect to the LiPlasome Patents, with LiPlasome on an ongoing basis. For
                                            this purpose, Chosa will procure that LiPlasome is copied on all correspondence (including
                                            patent agents and the like), to the extent that such correspondence is related to the LiPlasome
                                            Patents. In the event that Chosa does not wish to enforce, defend or Prosecute any LiPlasome
                                            Patent, Chosa shall immediately give notice to LiPlasome and provide LiPlasome with a reasonable
                                            opportunity to do so, and provide reasonable assistance to LiPlasome for this purpose. The
                                            same shall apply to any patent term extensions, adjustments, restorations or supplementary
                                            protection certificates with respect to the LiPlasome Patents.

 

    12

     

    

 

		7.6	If
                                            rights granted pursuant to the DRP® Companion Diagnostics License for the DRP® Companion
                                            Diagnostics are infringed or misappropriated by a Third Party or otherwise become the subject
                                            of legal or administrative proceedings, Chosa shall solely decide whether to pursue such
                                            infringement and all costs shall be borne by Chosa and all damages, fees, compensation, etc.
                                            and/or settlement amounts awarded or obtained during such proceedings/negotiations shall
                                            accrue to Chosa as well. The foregoing shall also apply with respect to defending such rights
                                            granted pursuant to the DRP® Companion Diagnostics License for the DRP® Companion
                                            Diagnostics in case of third-party claims of infringement by Chosa. Notwithstanding anything
                                            to the contrary, Chosa shall indemnify ALLARITY in full for any cost or other damages incurred
                                            by ALLARITY in connection with the enforcement by Chosa of its rights under this clause 7.6.

 

New
IPR

 

		7.7	Any
                                            discoveries, patents, utility models, designs, trademarks, know-how, software, screening
                                            data and other data, code, designs, documentation, techniques, materials, inventions, including
                                            applications, provisional applications, divisionals, continuations, continuations-in-part,
                                            reissues and re-examinations, and other work product in any form and on whatever media and
                                            any enhancements, improvements, upgrades, modifications and alterations thereto in any form,
                                            created, conceived, prepared, made, developed, originated and/or delivered (in whole or in
                                            part) by a Party or its sublicensees or subcontractors under this Agreement related to LiPlaCis
                                            shall be considered “New IPR” for the purpose of this Agreement. Such New IPR
                                            shall be and remain the sole and exclusive property of the creating Party. However, such
                                            New IPR created by LiPlasome, shall become part of the LiPlasome License subject to the terms
                                            of this Agreement. Any New IPR that relates to improvements of the DRP® Companion Diagnostics
                                            for which rights are granted pursuant to the DRP® Companion Diagnostics License shall
                                            also be owned by the creating Party, however, if such New IPR is created by ALLARITY, it
                                            shall become part of the DRP® Companion Diagnostics License in accordance with clause
                                            3.5 of this Agreement.

 

		7.8	The
                                            owner of the New IPR shall solely decide whether and where such New IPR shall be registered
                                            (file applications). All costs relating to such registration and maintenance shall be borne
                                            by Chosa if and only if Chosa agrees such New IPR shall be registered and included within
                                            the scope of this Agreement. Chosa shall cooperate with LiPlasome and ALLARITY in relation
                                            to the registration of such New IPR.

 

		7.9	Each
                                            of Chosa and LiPlasome shall promptly notify the other in writing in the event that it becomes
                                            aware of any facts that may affect the validity, scope or enforceability of New IPR.

 

		7.10	If
                                            any New IPR owned by LiPlasome or ALLARITY is infringed or misappropriated by a Third Party
                                            or otherwise becomes the subject of legal or administrative proceedings, Chosa and either
                                            LiPlasome or ALLARITY as applicable shall jointly decide whether to pursue such infringement
                                            and all costs shall be split equally. In case Chosa and LiPlasome or ALLARITY cannot agree
                                            whether to pursue infringements, either of Chosa and LiPlasome or ALLARITY shall be entitled
                                            to initiate proceedings/negotiations on its own, however, in such case the costs related
                                            to such proceedings/negotiations shall be borne by either of Chosa and LiPlasome or ALLARITY,
                                            as applicable, alone and all damages, fees, compensation, etc. and/or settlement amounts
                                            awarded or obtained during such proceedings/negotiations shall accrue to that Party as well.
                                            The foregoing shall also apply with respect to defending any New IPR in case of third-party
                                            claims of infringement pursued by either LiPlasome, ALLARITY or Chosa.

 

    13

     

    

 

Screening
data

 

		7.11	For
                                            the avoidance of doubt, the rights to the screening data related to LiPlaCis generated in
                                            LiPlasome prior to 15 February 2016 belong to LiPlasome, but is a part of the LiPlasome
                                            License, cf. clause 3.2.

 

		7.12	LiPlasome
                                            has a right to patient screening data generated by ALLARITY and Smerud related to LiPlacis
                                            after 15 February 2016, which is part of the LiPlasome License, cf. clause 3.2.

 

		8.	Non-competition

 

		8.1	ALLARITY
                                            shall not be entitled to develop Products within the Field for the Term of this Agreement.

 

		9.	Term
                                            and termination

 

		9.1	This
                                            Agreement shall come into force on the date of signing by the Parties (the “Effective
                                            Date”). This Agreement supersedes and replaces the Original Agreement which will terminate
                                            at the execution of this Agreement.

 

		9.2	The
                                            Parties shall prepare customary completion statements concerning the costs of maintenance
                                            and enforcement of the LiPlasome Patents.

 

		9.3	Any
                                            Party may terminate this Agreement giving thirty (30) days’ written notice to
                                            the other Party in the event that the other Party is in material breach of this Agreement
                                            and has not cured such material breach within the said thirty (30) days’ period.

 

		9.4	Upon
                                            termination of this Agreement, all rights granted herein and hereunder shall immediately
                                            terminate in relation to Chosa and Chosa and its sublicensees (if any) shall cease all exploitation
                                            of the Licenses as well as all sales of any products commercialized under the Licenses, and
                                            the Parties shall execute all such documents and do all such other acts as may be reasonably
                                            required to effectuate the termination of the Agreement. For the avoidance of doubt, any
                                            payments made under clause 5 above shall not be returned.

 

		9.5	Any
                                            outstanding payments under clause 5 shall be paid by Chosa to LiPlasome or ALLARITY,
                                            as applicable, no later than one (1) month following termination.

 

    14

     

    

 

		9.6	Upon
                                            termination of this Agreement,

 

		(i)	the
                                            LiPlasome License shall terminate and Chosa shall further deliver to LiPlasome (and will
                                            procure that its sublicensees and subcontractors deliver) all Proprietary Rights, the screening
                                            data related to LiPlaCis and all other documents (regardless of media) and other materials
                                            containing or evidencing confidential information, including, without limitation, all materials
                                            containing or evidencing know-how or other materials/documents related to the LiPlasome License,
                                            in such a manner as shall then be mutually agreed upon between LiPlasome and Chosa in good
                                            faith

 

		(ii)	the
                                            DRP® Companion Diagnostic License shall be deemed granted by ALLARITY to LiPlasome free
                                            of charge and the terms set forth in clauses 2, 3.5, 7, 9, 10, 11 and 13 of this Agreement
                                            shall apply mutadis mutandis between ALLARITY and LiPlasome for that purpose, and

 

		(iii)	Chosa
                                            will deliver to LiPlasome all documents (regardless of media) and other materials containing
                                            or evidencing confidential information, including, without limitation, all materials containing
                                            or evidencing know-how or other materials/documents related to the DRP® Companion Diagnostics
                                            License, in such a manner as shall then be mutually agreed upon between LiPlasome and Chosa
                                            in good faith.

 

		9.7	In
                                            the event that LiPlasome should enter into bankruptcy, reconstruction proceedings or similar,
                                            the Parties agree that Chosa shall be granted a first refusal right to take over and acquire
                                            the intellectual property rights necessary to ensure the uninterrupted continuation of the
                                            LiPlasome License rights as granted herein. This first right of refusal shall survive any
                                            transfer or assignment of the Agreement to a Third Party.

 

    15

     

    

 

		10.	Liability

 

		10.1	Any
                                            Party shall have the remedies generally available under Danish law in the event of a Party’s
                                            breach (including material breach) of its obligations under this Agreement.

 

		10.2	Except
                                            as otherwise expressly provided for under the terms of this Agreement, no right or remedy
                                            herein conferred upon or reserved to any Party is exclusive of any other right or remedy
                                            herein, or by law provided or permitted, but each shall be cumulative of any other right
                                            or remedy provided in this Agreement.

 

		10.3	Notwithstanding
                                            the above, in no event shall any Party be liable to the other for any lost revenues or profits
                                            or other indirect or consequential damages arising out of this Agreement.

 

		10.4	Furthermore,
                                            LiPlasome and ALLARITY shall not be liable for any product liability or any other loss (damages,
                                            loss of profits, loss of goodwill, other indirect losses, etc.) whatsoever that Chosa may
                                            incur in consequence of its exploitation of the LiPlasome License or the DRP® Companion
                                            Diagnostics License.

 

		10.5	Chosa
                                            shall indemnify, defend and hold each of LiPlasome and ALLARITY harmless from any and all
                                            claims from Third Parties for damage to property, personal injury and losses resulting there
                                            from, caused by or in any way connected with products commercialized under the License or
                                            DRP® Companion Diagnostics License; excepting claims arising solely from the negligence
                                            or willful misconduct of LiPlasome or ALLARITY, as applicable, or from their breach of any
                                            warranties under this Agreement.

 

		11.	Confidentiality

 

		11.1	Each
                                            Party shall keep all confidential information secret and confidential and shall not disclose
                                            the same or any part thereof to any third party. Such obligation shall not apply to information:

 

		●	Which
                                            is in the public domain at the time of disclosure;
	 	 	 

		●	which
                                            is published or otherwise becomes part of the public domain through no fault of the Party
                                            receiving the information;
	 	 	 

		●	which
                                            was in the possession of the receiving Party at the time of disclosure, as shown by prior
                                            written records, or becomes available from a third party who has the right to disclose it;

 

		●	which
                                            is independently developed by a Party, without reference to or use of any confidential information
                                            of the other, as shown by written records; and/or
	 	 	 

		●	which
                                            is required to be disclosed to any regulatory authority for the purpose of obtaining regulatory
                                            approvals or which is otherwise required to be disclosed by law or by mandatory rules or
                                            procedures applicable to a public traded company.

 

    16

     

    

 

		11.2	Each
                                            Party undertakes to ensure that its employees keep confidential information secret and confidential
                                            on the same terms as those applying to the Parties hereunder, both during and after their
                                            employment by that Party.

 

		11.3	In
                                            the event of a Party’s material breach of its obligations to maintain confidentiality
                                            as set forth in this clause 11, the Party in breach shall pay to the other Party an
                                            agreed penalty of DKK 250,000. This agreed penalty amount shall be paid for each separate
                                            instance of material breach. A Party’s payment of the agreed penalty shall not release
                                            such Party from its obligations of confidentiality as set forth in this Agreement or for
                                            payment of damages exceeding such penalty payment.

 

		11.4	The
                                            Parties’ obligations under this clause 11 shall survive the termination of this
                                            Agreement.

 

		11.5	Chosa
                                            shall have the sole right to publish the results and data of LiPlasome’s prior LiPlaCis
                                            Phase 1/2 study (“Prior Study”), provided that (i) all proposed publications
                                            or press releases (“Publication”) will be subject to customary ethical guidelines
                                            regarding authorship, accuracy, and attribution; (ii) any such Publication shall be subject
                                            to ALLARITY’s and LiPlasome's prior review and approval; and (iii) any approved Publication
                                            shall properly attribute the Prior Study, DRP® Companion Diagnostics and any related
                                            clinical trials to ALLARITY and LiPlasome, including by ensuring that any reference to the
                                            DRP® Companion Diagnostics includes a disclosure that the DRP® Companion Diagnostics
                                            is a registered trademark to ALLARITY and/or its Affiliates.

 

		11.6	Chosa
                                            shall not use ALLARITY’s registered trademarks for the DRP® Companion Diagnostics
                                            without the prior express written approval of ALLARITY, it being understood and agreed that
                                            (i) Chosa shall have a limited right and license to use ALLARITY’s registered DRP®
                                            Companion Diagnostics trademark solely for marketing and commercialization of the licensed
                                            DRP® Companion Diagnostics under this Agreement; (ii) Chosa shall include an appropriate
                                            reference in any marketing materials that the DRP® is a registered trademark of ALLARITY
                                            and the DRP® Companion Diagnostics are licensed technology of ALLARITY. ALLARITY shall
                                            have a right of inspection to confirm compliance with this Section 11.6 and to ensure the
                                            quality of the DRP® Companion Diagnostics offered under its trademarks.

 

		12.	Assignment

 

		12.1	Except
                                            as otherwise provided for in the Agreement, this Agreement or any of the rights or obligations
                                            hereunder may not be assigned or transferred, without the prior written consent of all such
                                            Parties, which shall not be unreasonably withheld.

 

		12.2	Notwithstanding
                                            the foregoing, a Party may without the prior written consent of the other Parties, assign
                                            this Agreement, including all rights and obligations under the Agreement, to a successor
                                            in connection with the share sale, asset sale, business combination or any other transaction
                                            of all or substantially all of such Party's business to a Third Party. Any such assignment
                                            shall not be deemed effective unless such assignee has agreed in writing to be bound by the
                                            terms and provisions of this Agreement. Any assignment of the Agreement in breach of this
                                            section 12.2 shall be null and void.

 

    17

     

    

 

		13.	Governing
                                            law and venue

 

		13.1	This
                                            Agreement shall be governed by and construed exclusively in accordance with Danish law without
                                            regard to its rules on the conflict of laws.

 

		13.2	Any
                                            dispute arising out of or in connection with this Agreement, including any disputes regarding
                                            the existence, validity or termination, shall be settled by arbitration in accordance with
                                            the Rules of Procedure of the Danish Institute of Arbitration in Copenhagen and in force
                                            at the time when such proceedings are commenced. The proceedings shall be conducted in accordance
                                            with the procedural rules of Danish law and in the Danish language. The seat of the arbitration
                                            shall be Copenhagen, Denmark. Nothing in this clause 12 shall prevent a Party from seeking
                                            injunctive relief with no provision of security.

 

*****

 

This
Agreement is executed in three (3) copies, each of which shall constitute an original.

 

[Signature
page follows]

 

    18

     

    

 

 

On
behalf of LiPlasome Pharma ApS:

 

		 	On behalf of Chosa ApS:
	 	 	 
	/s/ John Riis Mortensen	 	/s/ Peter Buhl
	John Riis Mortensen	 	Peter Buhl
	Chairman	 	 
	 	 	 
	/s/ Hans-Henrik Eriksen	 	
	Hans-Henrik Eriksen	 	 
	CEO	 	 
	 	 	 
	On behalf of Allarity Therapeutics Europe ApS:	 	 
	 	 	 
	/s/ Steve Carchedi	 	 
	Steve Carchedi	 	 

 

    19

     

    

 

Exhibit
A

 

DRP®
Companion Diagnostics Related Materials

 

 

20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]